[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 6087
1. Felix CA, Kolaris CP, Osheroff N: Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amst); 2006 Sep 8;5(9-10):1093-108
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review will summarize the evidence for topoisomerase II involvement in the genesis of translocations and extension of the model to acute leukemia in infants characterized by similar MLL translocations.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. DNA Topoisomerases, Type II / genetics. Leukemia / genetics. Models, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Base Sequence. Histone-Lysine N-Methyltransferase. Humans. Infant. Molecular Sequence Data. Myeloid-Lymphoid Leukemia Protein / genetics. Recombination, Genetic. Topoisomerase II Inhibitors

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857431.001).
  • [ISSN] 1568-7864
  • [Journal-full-title] DNA repair
  • [ISO-abbreviation] DNA Repair (Amst.)
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA77683; United States / NCI NIH HHS / CA / R01CA80175; United States / NCI NIH HHS / CA / R01CA85469; United States / NIGMS NIH HHS / GM / R01GM33944; United States / NIGMS NIH HHS / GM / R01GM53960
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / MLL protein, human; 0 / Topoisomerase II Inhibitors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 5.99.1.3 / DNA Topoisomerases, Type II
  • [Number-of-references] 219
  •  go-up   go-down


2. Thomas X, Pavan L, Le QH: [Adult acute lymphoblastic leukemia with central nervous system involvement: an overview]. Bull Cancer; 2008 Jul-Aug;95(7):707-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult acute lymphoblastic leukemia with central nervous system involvement: an overview].
  • [Transliterated title] Leucémies aiguës lymphoblastiques de l'adulte avec envahissement du système nerveux central : mise au point.
  • At the time of diagnosis, central nervous system (CNS) involvement is identified in less than 10% of adult acute lymphoblastic leukemia (ALL).
  • In CNS leukemia, innovative treatments and alternative delivery techniques are, however, warranted.
  • With effective CNS prophylaxis including intrathecal chemotherapy, high-dose systemic administration of certain agents and cranial irradiation, most adults with ALL without CNS disease at diagnosis may remain free of CNS leukemia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18755650.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 109
  •  go-up   go-down


3. Kantarjian HM: Purine Nucleosidase Phosphorylase (PNP): A novel target in leukemias and lymphomas. Semin Oncol; 2007 Dec;34(6 Suppl 5):S1-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086341.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Introductory Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Deoxyguanine Nucleotides; 0 / Enzyme Inhibitors; 2564-35-4 / deoxyguanosine triphosphate; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase
  •  go-up   go-down


Advertisement
4. Germano G, del Giudice L, Lo Nigro L, Polato K, Giarin E, Paganin M, Basso G: Comparative sequence analysis of incomplete DJH and TCR gene rearrangements in children with relapses of T-ALL. Leukemia; 2005 Sep;19(9):1687-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Gene Rearrangement, T-Lymphocyte. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Joining Region / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16015384.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Joining Region; 0 / Immunoglobulin Variable Region; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


5. Nigg C, Kolyvanos Naumann U, Käser L, Vetter W: [Splenomegaly. Main symptom: often asymptomatic splenic hyperplasia]. Praxis (Bern 1994); 2005 Mar 9;94(10):365-9; quiz 370
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Bone Marrow Examination. Diagnosis, Differential. Hemoglobin, Sickle / genetics. Heterozygote. Humans. Hypersplenism / diagnosis. Hypersplenism / etiology. Hypersplenism / pathology. Lymphatic Diseases / diagnosis. Lymphatic Diseases / etiology. Lymphatic Diseases / pathology. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Splenomegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794359.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Hemoglobin, Sickle
  •  go-up   go-down


6. Santoro A, Bica MG, Dagnino L, Agueli C, Salemi D, Cannella S, Veltroni M, Cetica V, Giarin E, Fabbiano F, Basso G, Arico M: Altered mRNA expression of PAX5 is a common event in acute lymphoblastic leukaemia. Br J Haematol; 2009 Sep;146(6):686-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered mRNA expression of PAX5 is a common event in acute lymphoblastic leukaemia.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19604238.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / RNA, Messenger
  •  go-up   go-down


7. Aref S, Salama O, Shamaa S, El-Refaie M, Mourkos H: Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia. Hematology; 2007 Aug;12(4):319-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia.
  • The angiogenic status and the exact role of the angiogenic cytokines in lymphoid leukemia has not been fully elucidated.
  • We have investigated the profile of the systemic components of angiogenic regulation in B-lineage acute lymphoblastic leukemia (B-ALL) and B-chronic lymphocytic leukemia (B-CLL), namely vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-alpha), endostatin and matrix metalloproteinase-9 (MMP-9) using enzyme-linked immunosorbent assay (ELISA).
  • [MeSH-major] Angiogenic Proteins / blood. Burkitt Lymphoma / blood. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Neoplasm Proteins / blood

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17654059.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Angiogenic Proteins; 0 / Endostatins; 0 / Neoplasm Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


8. Whittle AM, Ali S: Primary prophylaxis with voriconazole in patients receiving induction chemotherapy on the MRC adult acute lymphoblastic leukaemia trial (UK-ALL XII) to avoid itraconazole-enhanced vinca neurotoxicity. Int J Lab Hematol; 2008 Apr;30(2):173-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary prophylaxis with voriconazole in patients receiving induction chemotherapy on the MRC adult acute lymphoblastic leukaemia trial (UK-ALL XII) to avoid itraconazole-enhanced vinca neurotoxicity.
  • [MeSH-major] Antifungal Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Itraconazole / therapeutic use. Mycoses / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / therapeutic use. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. Itraconazole .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333850.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 304NUG5GF4 / Itraconazole; JFU09I87TR / Voriconazole
  •  go-up   go-down


9. Brydøy M, Fosså SD, Dahl O, Bjøro T: Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol; 2007;46(4):480-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, a recent long-term follow-up study reported a prevalence of POF in young females with Hodgkin's lymphoma of 37% showing that young age at time of treatment only delays the development of POF.
  • Persistent azoospermia was formerly common after treatment for Hodgkin's lymphoma, but currently, most patients recover spermatogenesis.
  • Modern treatment of childhood acute lymphoblastic leukemia is also unlikely to cause infertility.


10. Greaves M: Godwits and blast crises: in memory of David Galton. Leuk Lymphoma; 2007 Dec;48(12):2280-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Blast Crisis / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18066984.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Moleti ML, Testi AM, Giona F, Malandruccolo L, Pescarmona E, Martino P, Paoloni F, Barberi W, Palumbo G, Mandelli F, Foa R: CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience. Leuk Lymphoma; 2007 Mar;48(3):551-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience.
  • During the last 15 years, we have used the National Cancer Institute (NCI) 89-C-41 protocol in patients aged younger than 21 years with Burkitt's leukemia/lymphoma (BLL) and diffuse large B-cell lymphoma (DLBCL).
  • Two responders relapsed after 2 months and one presented early B acute lymphoblastic leukemia 33 months from the end of therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Leukemia / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454598.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  •  go-up   go-down


12. Haouas H, Haouas S, Uzan G, Hafsia A: Identification of new markers discriminating between myeloid and lymphoid acute leukemia. Hematology; 2010 Aug;15(4):193-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of new markers discriminating between myeloid and lymphoid acute leukemia.
  • BACKGROUND: The heterogeneity of acute myeloid leukemia (AML) with respect to biology and clinical course resides in the fact that patients belonging to the same group show marked differences in their response to chemotherapy, necessitating a refinement of AML classification.
  • RESULTS: We have shown that two downregulated genes in AML, those encoding guanine nucleotide-binding protein gamma11 (GNG11) and amphiregulin (AREG), are also downregulated in B-lineage acute lymphoblastic leukemia (B-ALL) and T-lineage acute lymphoblastic leukemia (T-ALL) patients.
  • Our study is the first to analyze these genes in AML, B-ALL, T-ALL and chronic leukemia (myeloid and lymphoid) patients by RT-PCR.
  • This rapid and sensitive method could be used to screen these genes in different types of leukemia.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Amphiregulin. Cell Line, Tumor. Ceruloplasmin / genetics. Ceruloplasmin / metabolism. Diagnosis, Differential. EGF Family of Proteins. Female. GTP-Binding Protein alpha Subunits, Gq-G11 / genetics. GTP-Binding Protein alpha Subunits, Gq-G11 / metabolism. Gene Expression Profiling. Glycoproteins / genetics. Glycoproteins / metabolism. Humans. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20670477.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AREG protein, human; 0 / Amphiregulin; 0 / Biomarkers, Tumor; 0 / EGF Family of Proteins; 0 / Glycoproteins; 0 / Intercellular Signaling Peptides and Proteins; EC 1.16.3.1 / Ceruloplasmin; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gq-G11
  •  go-up   go-down


13. Mantadakis E, Katzilakis N, Foundoulaki E, Kalmanti M: Moderate intravenous sedation with fentanyl and midazolam for invasive procedures in children with acute lymphoblastic leukemia. J Pediatr Oncol Nurs; 2009 Jul-Aug;26(4):217-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Moderate intravenous sedation with fentanyl and midazolam for invasive procedures in children with acute lymphoblastic leukemia.
  • Data were collected prospectively on 100 consecutive invasive procedures, that is, lumbar and bone marrow punctures (alone or in combination), in 16 patients less than 21 years of age with acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Fentanyl / therapeutic use. Midazolam / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. FENTANYL .
  • Hazardous Substances Data Bank. Midazolam .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19726793.001).
  • [ISSN] 1043-4542
  • [Journal-full-title] Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses
  • [ISO-abbreviation] J Pediatr Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anesthetics, Dissociative; 0 / Anesthetics, Intravenous; R60L0SM5BC / Midazolam; UF599785JZ / Fentanyl
  •  go-up   go-down


14. Yao L, Chen Z, Cen J, Liang J, Feng Y, He J, Qi X, Shen H: The pattern of clonal immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements in Chinese adult acute lymphoblastic leukemia patients. Leuk Res; 2008 Nov;32(11):1735-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pattern of clonal immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements in Chinese adult acute lymphoblastic leukemia patients.
  • [MeSH-major] Gene Rearrangement. Gene Rearrangement, delta-Chain T-Cell Antigen Receptor / genetics. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Genes, Immunoglobulin / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18456325.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


15. Zhu L, Wang HX, Lui J, Yan HM, Xue M: [Acute leukemia relapse of donor origin in two cases after haploidentical bone marrow transplantation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr;14(2):400-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute leukemia relapse of donor origin in two cases after haploidentical bone marrow transplantation].
  • To investigate the leukemia relapse of AL patients after HLA haploidentical bone marrow transplantation (HLA HBMT), 2 relapsed leukemia patients received HLA HBMT were studied, peripheral blood simples and bone marrow smear were examined, morphologic change of bone marrow cells was observed, while the HLA genotype and chromosome karyotye were analyzed by PCR and routine G-banding methods, respectively.
  • The results indicated that the two cases were diagnosed primarily as acute lymphocytic leukemia (common cell subtype) and acute megakaryocytic leukemia, in which chromosome abnormalities or activation of protooncogene in leukemic cells were observed.
  • The complete hematopuietie reconstitution of donor origin was obtained in these 2 cases after HLA HBMT, but the leukemic cells in these 2 leukemia patients were confirmed to be donor origin after relapse, their blood groups and HLA genotype were found to be originated from donor.
  • These 2 relapsed leukemia patients were diagnosed as acute lymphocytic leukemia (B cell subtype) and acute megakaryocytic leukemia.
  • It is suggested that high-dose of immunosuppressive agents used in transplantation may contribute to leukemia relapse of donor origin in these patients.
  • Abnormalities in hematopoietic microenvironment may be also involved in the leukemia development.
  • Donor-cell leukemia after allogeneic hematopoietic stem cell transplantation can be an ideal model to investigate the related events in human leukemogenesis.

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638225.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


16. Yamaji K, Okamoto T, Yokota S, Watanabe A, Horikoshi Y, Asami K, Kikuta A, Hyakuna N, Saikawa Y, Ueyama J, Watanabe T, Okada M, Taga T, Kanegane H, Kogawa K, Chin M, Iwai A, Matsushita T, Shimomura Y, Hori T, Tsurusawa M, Japanese Childhood Cancer Leukemia Study Group: Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer; 2010 Dec 15;55(7):1287-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.
  • BACKGROUND: The majority of minimal residual disease (MRD)-positive patients with acute lymphoblastic leukemia (ALL) have poor outcomes.
  • PROCEDURE: Between 2000 and 2004, 305 eligible patients with precursor B or T-cell ALL were enrolled in the ALL2000 study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


17. Ahmad F, Dalvi R, Chavan D, Das BR, Mandava S: Cytogenetic profile of acute lymphocytic leukemia patients: report of a novel translocation t(4;13) (q21 x 3; q35) from an Indian population. Hematology; 2008 Feb;13(1):28-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic profile of acute lymphocytic leukemia patients: report of a novel translocation t(4;13) (q21 x 3; q35) from an Indian population.
  • Acute lymphocytic leukemia (ALL) is a malignant neoplasm characterized by clonal proliferation, decreased apoptosis and accumulation of immature lymphoid cells in the bone marrow as well as the peripheral blood.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 13 / genetics. Chromosomes, Human, Pair 4 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18534063.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Nishii K, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group: Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica; 2008 Feb;93(2):287-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
  • To identify factors associated with relapse-free survival (RFS), 80 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, enrolled in a phase II study of imatinib-combined chemotherapy, were analyzed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Philadelphia Chromosome. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223280.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


19. de Jonge R, Hooijberg JH, van Zelst BD, Jansen G, van Zantwijk CH, Kaspers GJ, Peters GJ, Ravindranath Y, Pieters R, Lindemans J: Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood; 2005 Jul 15;106(2):717-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia.
  • Ex vivo MTX sensitivity of lymphoblasts obtained from pediatric patients with acute lymphoblastic leukemia (ALL; n = 157) was determined by the in situ thymidylate synthase inhibition assay after either continuous (21 hours; TSI(50, cont)) or short-term (3 hours; TSI(50, short)) MTX exposure.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Folic Acid / genetics. Methotrexate / pharmacology. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827858489 for PMID:15797993 [PharmGKB] .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Blood. 2005 Aug 15;106(4):1198. Jansen, Gerritz [corrected to Jansen, Gerrit]; van Zantwijk, Christine H [corrected to van Zantwijk, Christina H]; Kaspers, Gert Jan L [corrected to Kaspers, Gertjan J L]; Peters, Frits G J [corrected to Peters, Godefridus J]
  • (PMID = 15797993.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 935E97BOY8 / Folic Acid; EC 1.18.1.- / methionine synthase reductase; EC 1.18.1.2 / Ferredoxin-NADP Reductase; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.2.1 / Glycine Hydroxymethyltransferase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


20. Qiuping Z, Jie X, Youxin J, Qun W, Wei J, Chun L, Jin W, Yan L, Chunsong H, Mingzhen Y, Qingping G, Qun L, Kejian Z, Zhimin S, Junyan L, Jinquan T: Selectively frequent expression of CXCR5 enhances resistance to apoptosis in CD8(+)CD34(+) T cells from patients with T-cell-lineage acute lymphocytic leukemia. Oncogene; 2005 Jan 20;24(4):573-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selectively frequent expression of CXCR5 enhances resistance to apoptosis in CD8(+)CD34(+) T cells from patients with T-cell-lineage acute lymphocytic leukemia.
  • We investigated CD4(+)CD34(+), CD8(+)CD34(+), CD4(+)CD34(-), and CD8(+)CD34(-) T cells from cord blood and from typical patients with T-cell-lineage acute lymphocytic leukemia and T-cell-lineage chronic lymphocytic leukemia in terms of expression and functions of CXCR5/CXCL13.
  • We found that CXCR5 was selectively frequently expressed on T-cell-lineage acute (chronic) lymphocytic leukemia (T-ALL) CD8(+)CD34(+) T cells, but not on T-ALL CD4(+)CD34(+), CD4(+)CD34(-), and CD8(+)CD34(-) T cells.
  • [MeSH-major] Antigens, CD34 / metabolism. Apoptosis. CD8-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Receptors, Cytokine / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Oncogene. 2011 Jun 16;30(24):2798 [21677655.001]
  • (PMID = 15580304.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ANP32B protein, human; 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, CD34; 0 / BIRC7 protein, human; 0 / CXCL13 protein, human; 0 / CXCR5 protein, human; 0 / Chemokine CXCL13; 0 / Chemokines, CXC; 0 / Inhibitor of Apoptosis Proteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Receptors, CXCR5; 0 / Receptors, Chemokine; 0 / Receptors, Cytokine; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


21. IMAHASHI N, TOKUNAGA M, NISHIWAKI S, YANAGISAWA M, OZAWA Y, MIYAMURA K: Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation. Rinsho Ketsueki; 2009 Nov;50(11):1612-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation.
  • The prognosis of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+)ALL) relapsing after allogeneic hematopoietic stem cell transplantation is dismal.
  • Our case suggests that by continuing imatinib after the induction of molecular remission by imatinib-combined chemotherapy, the antileukemic activity of imatinib could achieve durable remission in combination with the graft-versus-leukemia effect.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / administration & dosage
  • [MeSH-minor] Benzamides. Disease-Free Survival. Drug Administration Schedule. Female. Graft vs Leukemia Effect. Humans. Imatinib Mesylate. Middle Aged. Remission Induction. Transplantation, Homologous. Treatment Outcome


22. DeJong M, Fombonne E: Citalopram to treat depression in pediatric oncology. J Child Adolesc Psychopharmacol; 2007 Jun;17(3):371-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Central Nervous System Neoplasms / psychology. Child. Craniopharyngioma / psychology. Female. Humans. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology

  • Genetic Alliance. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17630871.001).
  • [ISSN] 1044-5463
  • [Journal-full-title] Journal of child and adolescent psychopharmacology
  • [ISO-abbreviation] J Child Adolesc Psychopharmacol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Serotonin Uptake Inhibitors; 0DHU5B8D6V / Citalopram
  •  go-up   go-down


23. Hemsworth S, Nunn AJ, Selwood K, Osborne C, Jones A, Pizer B: Once-daily netilmicin for neutropenic pyrexia in paediatric oncology. Acta Paediatr; 2005 Mar;94(3):268-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Brain Neoplasms / drug therapy. Child. Drug Monitoring. Female. Humans. Infant. Infusions, Intravenous. Lymphoma, Non-Hodgkin / drug therapy. Male. Neutropenia / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Fever.
  • Hazardous Substances Data Bank. NETILMICIN .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028643.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 4O5J85GJJB / Netilmicin
  •  go-up   go-down


24. Robinson KE, Livesay KL, Campbell LK, Scaduto M, Cannistraci CJ, Anderson AW, Whitlock JA, Compas BE: Working memory in survivors of childhood acute lymphocytic leukemia: functional neuroimaging analyses. Pediatr Blood Cancer; 2010 Apr;54(4):585-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Working memory in survivors of childhood acute lymphocytic leukemia: functional neuroimaging analyses.
  • PROCEDURE: This study used functional neuroimaging techniques to examine working memory and executive functioning deficits of survivors of childhood acute lymphocytic leukemia (ALL), as compared to age- and gender-matched healthy controls.

  • MedlinePlus Health Information. consumer health - Memory.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 2002 Jun;125(Pt 6):1275-82 [12023316.001]
  • [Cites] Med Pediatr Oncol. 2003 Feb;40(2):88-92 [12461791.001]
  • [Cites] Biol Psychiatry. 2003 Mar 1;53(5):376-84 [12614990.001]
  • [Cites] Dev Psychol. 2003 Jul;39(4):761-76 [12859128.001]
  • [Cites] Hum Brain Mapp. 2003 Oct;20(2):51-8 [14505331.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1021:296-309 [15251900.001]
  • [Cites] Eur J Cancer. 2004 Sep;40(14):2082-90 [15341983.001]
  • [Cites] Child Dev. 2004 Sep-Oct;75(5):1357-72 [15369519.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):387-400 [9143382.001]
  • [Cites] Neuroimage. 2005 Jan 1;24(1):61-9 [15588597.001]
  • [Cites] Hum Brain Mapp. 2005 May;25(1):46-59 [15846822.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 2005 Summer;17(3):357-63 [16179658.001]
  • [Cites] Cancer. 2005 Dec 1;104(11 Suppl):2557-64 [16247780.001]
  • [Cites] Hum Brain Mapp. 2006 Jan;27(1):28-36 [16001441.001]
  • [Cites] Hum Brain Mapp. 2006 May;27(5):392-401 [16596654.001]
  • [Cites] Ann N Y Acad Sci. 2006 Dec;1094:226-34 [17347354.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):65-73 [16628558.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Apr;29(4):792-7 [18184841.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):99-104 [18322925.001]
  • (PMID = 19953649.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA068485-13S4; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCI NIH HHS / CA / CA068485; United States / NCI NIH HHS / CA / P30 CA068485-13S4
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS183910; NLM/ PMC2901833
  •  go-up   go-down


25. Paydas S, Yavuz S, Disel U: Feasibility of FLAG-IDA regimen in cases with relapsed/refractory acute leukemia cases. Ann Hematol; 2006 Jan;85(1):63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of FLAG-IDA regimen in cases with relapsed/refractory acute leukemia cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16252088.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; ZRP63D75JW / Idarubicin; FLAG protocol
  •  go-up   go-down


26. Bacher U, Kohlmann A, Haferlach T: Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies. Cancer Treat Rev; 2010 Dec;36(8):637-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies.
  • Considering the heterogeneity of haematological malignancies, the growing arsenal of compounds, allowing targeted therapy, e.g. in myelodysplastic syndromes (MDS) or chronic myeloid leukaemia (CML), and the more differentiated indication to allogeneic stem cell transplantation, routine diagnostic procedures would highly benefit from an introduction of this novel methodology: by now, the majority of genetically defined leukaemia subtypes has been accurately reproduced on the basis of distinct gene expression patterns by various independent research groups.
  • Moreover, classification of histomorphologically overlapping lymphoma subentities (e.g.
  • Burkitt lymphoma and diffuse large B-cell lymphoma, DLBCL), was considerably improved by GEP.
  • In a high proportion of Philadelphia positive acute lymphoblastic leukaemia (ALL) patients, prognostically adverse deletions of the IKZF1 gene coding for a specific transcription factor were identified with GEP analysis, which revealed new insights in the clinical variability of this disorder.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation / methods. Combined Modality Therapy. Female. Gene Expression Regulation, Leukemic. Genetic Predisposition to Disease. Hematopoietic Stem Cell Transplantation / methods. Humans. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Male. Microarray Analysis. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20570445.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


27. Gaynon PS, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Hawks R, Steele D, Zipf T, Stram DO, Villaluna D, Trigg ME: Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. J Clin Oncol; 2006 Jul 1;24(19):3150-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.
  • PURPOSE: To compare conventional sibling bone marrow transplantation (CBMT), BMT with alternative donor (ABMT), and chemotherapy (CT) for children with acute lymphoblastic leukemia (ALL) and an early first marrow relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Neoplasms / surgery. Bone Marrow Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery


28. Bueso-Ramos C, Xu Y, McDonnell TJ, Brisbay S, Pierce S, Kantarjian H, Rosner G, Garcia-Manero G: Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. J Clin Oncol; 2005 Jun 10;23(17):3932-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status.
  • PURPOSE: To study the relationship between protein expression and DNA methylation of a triad of cell-cycle regulatory genes known to be frequently methylated in adult acute lymphocytic leukemia (ALL).
  • [MeSH-major] Cell Cycle Proteins / metabolism. DNA Methylation. DNA-Binding Proteins / metabolism. Nuclear Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Tumor Suppressor Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15851765.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA100067; United States / NCI NIH HHS / CA / CA105771
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1C protein, human; 0 / CDKN2B protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p57; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / Enzyme Inhibitors; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


29. Magrath I, Shanta V, Advani S, Adde M, Arya LS, Banavali S, Bhargava M, Bhatia K, Gutiérrez M, Liewehr D, Pai S, Sagar TG, Venzon D, Raina V: Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected]. Eur J Cancer; 2005 Jul;41(11):1570-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected].
  • In the 1970s, survival rates after treatment for acute lymphoblastic leukaemia (ALL) in children and young adults (less than 25 years) in India were poor, even in specialised cancer centres.
  • The proportions of ALLs with precursor T-cell immunophenotypes, particularly in Chennai, were also increased, even when differences in the age distribution were taken into consideration (in <18-year olds, the range was 21.1-42.7%), and in molecular analyses performed on leukaemic cells from over 250 patients less than 21-years-old with precursor B-cell ALL, a lower frequency of TEL-AML1-positive ALL cases than reported in Western series was observed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Cancer. 2007 Feb;43(3):632. Raina, V [added]
  • (PMID = 16026693.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 36
  •  go-up   go-down


30. Apostolidou E, Swords R, Alvarado Y, Giles FJ: Treatment of acute lymphoblastic leukaemia : a new era. Drugs; 2007;67(15):2153-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute lymphoblastic leukaemia : a new era.
  • Acute lymphocytic leukaemia (ALL) is a heterogeneous group of disorders that result from the clonal proliferation and expansion of malignant lymphoid cells in the bone marrow, blood and other organs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2000;46(5):427-32 [11127949.001]
  • [Cites] Leuk Lymphoma. 2000 Jan;36(3-4):263-73 [10674898.001]
  • [Cites] Semin Oncol. 2005 Apr;32(2 Suppl 2):S5-8 [15818537.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1765-9 [16721371.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(6):521-31 [9118464.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1167-73 [12637486.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):832-8 [16467096.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1986 Summer;8(2):99-104 [3526939.001]
  • [Cites] Leuk Lymphoma. 1993;10 Suppl:147-50 [8481663.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2549-55 [17041099.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2814-22 [1835410.001]
  • [Cites] Blood. 2007 Apr 1;109 (7):2744-50 [17132721.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2379-86 [12791647.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6615-24 [16166440.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):69-72 [10690390.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1464-8 [15054472.001]
  • [Cites] Curr Med Chem. 1999 Apr;6(4):329-52 [10101216.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):127-34 [9654112.001]
  • [Cites] Curr Opin Investig Drugs. 2005 Jun;6(6):623-30 [15988914.001]
  • [Cites] J Natl Cancer Inst. 1990 Oct 17;82(20):1641-2 [2145440.001]
  • [Cites] Clin Transl Oncol. 2006 Aug;8(8):560-5 [16952844.001]
  • [Cites] Anticancer Drugs. 1993 Feb;4(1):37-48 [8457713.001]
  • [Cites] Rev Pneumol Clin. 2005 Sep;61(4 Pt 2):4S5-7 [16273001.001]
  • [Cites] Pharmacol Ther. 1991 Oct;52(1):35-84 [1687171.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):401-12 [15923057.001]
  • [Cites] Int J Clin Pharmacol Ther. 2005 Dec;43(12):567-9 [16372519.001]
  • [Cites] Circ Res. 1999 Aug 6;85(3):221-8 [10436164.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10 (16):5335-41 [15328169.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1639-45 [16087696.001]
  • [Cites] Cancer Res. 1977 Feb;37(2):535-40 [264412.001]
  • [Cites] J Med Chem. 2002 Oct 24;45(22):4913-22 [12383017.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4937-43 [10519407.001]
  • [Cites] Biochem Pharmacol. 2003 Apr 1;65(7):1163-70 [12663051.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5929-37 [16135464.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5601-7 [6352020.001]
  • [Cites] Mol Pharmacol. 1995 Sep;48(3):459-71 [7565626.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] Blood. 2007 May 15;109 (10 ):4164-7 [17264295.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):253-65 [15057285.001]
  • [Cites] N Engl J Med. 1986 Sep 11;315(11):657-63 [2943992.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;33(5):359-65 [8306408.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Sep 26;55(10 ):1293-302 [14499708.001]
  • [Cites] Cell Prolif. 1992 Nov;25(6):523-36 [1457603.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Carbohydr Res. 1985 Feb 28;136:391-6 [4005892.001]
  • [Cites] Invest New Drugs. 1999;17(1):81-7 [10555126.001]
  • [Cites] Lancet. 1987 Apr 4;1(8536):786-9 [2882192.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(6):461-70 [9788572.001]
  • [Cites] Leukemia. 1998 May;12(5):660-5 [9593262.001]
  • [Cites] Biochem Pharmacol. 2001 Apr 1;61(7):857-65 [11274972.001]
  • [Cites] Leukemia. 1997 Dec;11(12):2039-44 [9447817.001]
  • [Cites] Lancet Oncol. 2005 Aug;6(8):548 [16094758.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Nov;4(11):804-5 [17143248.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):649-55 [11531245.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1583-9 [8453627.001]
  • [Cites] Ann Pharmacother. 1997 May;31(5):616-24 [9161659.001]
  • [Cites] Invest New Drugs. 1986;4(1):85-105 [3516918.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Sep;54(3):273-81 [15173957.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5136-42 [17344466.001]
  • [Cites] J Med Chem. 1994 Jul 8;37(14):2167-74 [8035423.001]
  • [Cites] Bioorg Med Chem Lett. 2001 Jul 9;11(13):1671-3 [11425534.001]
  • [Cites] Blood. 1997 Feb 1;89(3):1013-8 [9028333.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1328-33 [16614241.001]
  • [Cites] J Med Chem. 1993 Mar 19;36(6):758-64 [8459402.001]
  • [Cites] Anticancer Drugs. 2002 Sep;13(8):797-805 [12394263.001]
  • [Cites] Eur J Haematol. 2006 Oct;77(4):293-9 [16856922.001]
  • [Cites] Int J Cancer. 2004 Jul 10;110(5):767-74 [15146568.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(4):351-5 [8548881.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7161-7 [16192600.001]
  • [Cites] Nat Genet. 2004 May;36(5):453-61 [15098032.001]
  • [Cites] EMBO J. 2002 Nov 1;21(21):5766-74 [12411494.001]
  • [Cites] Bone Marrow Transplant. 1998 Dec;22(12):1137-43 [9894715.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):199-203 [9428769.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):896-904 [7547237.001]
  • [Cites] J Med Chem. 2001 Dec 6;44(25):4416-30 [11728187.001]
  • [Cites] Mol Pharmacol. 1995 Oct;48(4):758-65 [7476904.001]
  • [Cites] Clin Lung Cancer. 2004 Apr;5 Suppl 2:S75-9 [15117429.001]
  • [Cites] Adv Exp Med Biol. 1984;165 Pt B:309-14 [6609537.001]
  • [Cites] Cancer. 1976 Jan;37(1):220-8 [1061636.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11598-602 [8265596.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2155-60 [8374873.001]
  • [Cites] Leukemia. 1999 Mar;13(3):335-42 [10086723.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2A):1277-83 [10368688.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1203-9 [10506705.001]
  • [Cites] Annu Rev Med. 1997;48:353-74 [9046968.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] J Med Chem. 1998 Dec 17;41(26):5310-9 [9857098.001]
  • [Cites] Cancer Chemother Pharmacol. 2001;47(2):179-84 [11269745.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):120-7 [16331634.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Apr;57(4):427-35 [16322992.001]
  • [Cites] Int J Exp Pathol. 2002 Feb;83(1):21-38 [12059907.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72 (5):844-50 [9311603.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):697-705 [10080616.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):114-41; discussion 200-2 [12196212.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):727-37 [9615712.001]
  • [Cites] Adv Exp Med Biol. 1993;338:461-4 [8304158.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3658-61 [11369666.001]
  • [Cites] Cancer. 1994 May 15;73(10):2515-9 [8174048.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Feb;15(1):163-205 [11253606.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1702-6 [8137285.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1479-84 [8137251.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2449-56 [16258975.001]
  • [Cites] Leukemia. 1992;6 Suppl 2:148-52 [1578919.001]
  • [Cites] Biochemistry. 1997 Apr 15;36(15):4399-411 [9109647.001]
  • [Cites] J Med Chem. 1991 Feb;34(2):574-9 [1995880.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Apr;26(4):217-26 [15087948.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jan;5(1):17-8 [16485343.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5329-35 [17000665.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2542-51 [16775235.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):982-92 [15709163.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Sep;298(3):1206-12 [11504822.001]
  • [Cites] Biochem Pharmacol. 1996 May 17;51(10):1331-40 [8787549.001]
  • [Cites] Curr Opin Oncol. 2001 Jan;13(1):14-20 [11148680.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1780-6 [8355045.001]
  • [Cites] Mol Cancer Ther. 2002 Feb;1(4):275-86 [12467223.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Eur J Cancer. 1991;27(4):482-7 [1827725.001]
  • [Cites] Expert Opin Investig Drugs. 2003 May;12(5):853-63 [12720495.001]
  • [Cites] Jpn J Cancer Res. 1998 Sep;89(9):954-62 [9818032.001]
  • [Cites] Nat Rev Drug Discov. 2005 May;Suppl:S16-7 [15962527.001]
  • [Cites] Pediatr Nurs. 1995 Sep-Oct;21(5):471-4, 490 [8684851.001]
  • [Cites] Biochemistry. 1964 Jan;3:15-8 [14114497.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Jul;50(1):6-8 [12111105.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Biochem Biophys Res Commun. 1972 May 26;47(4):685-91 [5026289.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3036-50 [9679969.001]
  • [Cites] Cancer Res. 1976 Apr;36(4):1499-502 [1260766.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1986-94 [11877270.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4341-4 [11389057.001]
  • [Cites] Hematol J. 2002;3(1):2-6 [11960387.001]
  • [Cites] Clin Cancer Res. 1996 Nov;2(11):1843-9 [9816139.001]
  • [Cites] Clin Colorectal Cancer. 2005 Nov;5(4):257-62 [16356302.001]
  • [Cites] Leuk Lymphoma. 1993;10 Suppl:153-7 [8481665.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3288-94 [16368880.001]
  • [Cites] J Clin Oncol. 1988 Apr;6(4):583-7 [3282032.001]
  • [Cites] Cancer Res. 1990 Jul 15;50(14):4260-6 [2194651.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1421-3 [16601247.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Biochem Pharmacol. 1998 Apr 15;55(8):1229-34 [9719477.001]
  • (PMID = 17927282.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Folic Acid Antagonists; 0 / Nucleosides; 0 / Oncogene Proteins v-abl; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr
  • [Number-of-references] 159
  •  go-up   go-down


31. Plensa E, Ribera JM, Oriol A, Bethencourt C, Parody R, Hernández Ribas JM, Moreno MJ, del Potro E, Tormo M, Rivas C, Besalduch J, Sanz MA, Arias J, Fernández Calvo J, Moraleda JM, Bueno J, Feliu E, Ortega JJ, Grupo PETHEMA: [Prevalence and prognostic significance of myeloid markers in adults with high-risk acute lymphoblastic leukemia]. Med Clin (Barc); 2005 Sep 3;125(7):241-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prevalence and prognostic significance of myeloid markers in adults with high-risk acute lymphoblastic leukemia].
  • [Transliterated title] Prevalencia y significado pronóstico de los marcadores mieloides en adultos con leucemia aguda linfoblástica de alto riesgo.
  • BACKGROUND AND OBJECTIVE: The prognostic value of myeloid antigen expression in adult acute lymphoblastic leukemia (ALL) is controversial.
  • [MeSH-major] Antigens, CD / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16137483.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


32. Beesley AH, Rampellini JL, Palmer ML, Heng JY, Samuels AL, Firth MJ, Ford J, Kees UR: Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia. Mol Cancer; 2010;9:284
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia.
  • BACKGROUND: Rearrangement of the mixed-lineage leukemia gene (MLL) is found in 80% of infant acute lymphoblastic leukemia (ALL) and is associated with poor prognosis and resistance to glucocorticoids (GCs).
  • [MeSH-major] DNA Damage / genetics. Drug Resistance, Neoplasm / genetics. Glucocorticoids / pharmacology. Lymphocytes / drug effects. Myeloid-Lymphoid Leukemia Protein / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7853-8 [12782787.001]
  • [Cites] Nature. 2010 Sep 16;467(7313):343-6 [20818375.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Leukemia. 2004 Mar;18(3):521-9 [14712291.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1881-6 [7655016.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3861-8 [7579354.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1270-8 [9552025.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1344-8 [9737681.001]
  • [Cites] Blood. 1999 Jul 1;94(1):283-90 [10381524.001]
  • [Cites] Br J Haematol. 2005 Apr;129(2):189-98 [15813846.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):175-88 [15826832.001]
  • [Cites] BMC Genomics. 2005;6:59 [15854232.001]
  • [Cites] Eur J Cancer. 2005 Jun;41(9):1300-3 [15869873.001]
  • [Cites] Blood. 2005 Jul 1;106(1):345-52 [15774615.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):24315-21 [15851483.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7387-8 [10602495.001]
  • [Cites] FASEB J. 2001 Mar;15(3):693-9 [11259387.001]
  • [Cites] Leukemia. 2002 May;16(5):949-51 [11986959.001]
  • [Cites] Leukemia. 2003 Apr;17(4):700-6 [12682627.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1289-95 [16200064.001]
  • [Cites] Br J Haematol. 2005 Nov;131(4):447-56 [16281934.001]
  • [Cites] Br J Haematol. 2006 Mar;132(5):539-51 [16445826.001]
  • [Cites] Blood. 2006 Mar 1;107(5):2061-9 [16293608.001]
  • [Cites] Leukemia. 2006 Jan;20(1):179-82 [16307022.001]
  • [Cites] Leukemia. 2006 May;20(5):777-84 [16511515.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4591-601 [16651409.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4663-5 [16478880.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Aug;45(8):754-60 [16688745.001]
  • [Cites] Blood. 2006 Jul 15;108(2):441-51 [16556894.001]
  • [Cites] Br J Cancer. 2006 Dec 4;95(11):1537-44 [17117183.001]
  • [Cites] Br J Haematol. 2007 Apr;137(2):109-16 [17391490.001]
  • [Cites] Genes Dev. 2007 Oct 1;21(19):2385-98 [17908926.001]
  • [Cites] Leuk Lymphoma. 2007 Oct;48(10):2083-6 [17917979.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):823-33 [17957188.001]
  • [Cites] Int J Hematol. 2008 Jan;87(1):10-8 [18224408.001]
  • [Cites] Br J Haematol. 2008 Mar;140(6):716-9 [18218047.001]
  • [Cites] Leuk Res. 2009 Feb;33(2):321-5 [18789525.001]
  • [Cites] Apoptosis. 2009 Jun;14(6):821-8 [19421859.001]
  • [Cites] Science. 2009 May 22;324(5930):1029-33 [19460998.001]
  • [Cites] BMC Cancer. 2009;9:147 [19445675.001]
  • [Cites] Br J Cancer. 2009 Jun 16;100(12):1926-36 [19436302.001]
  • [Cites] EMBO J. 2009 Oct 21;28(20):3185-95 [19763085.001]
  • [Cites] Blood. 2009 Nov 5;114(19):4169-78 [19749093.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4882-7 [12941810.001]
  • (PMID = 20979663.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  • [Other-IDs] NLM/ PMC2987983
  •  go-up   go-down


33. Wu MY: [State of arts in therapy of childhood acute lymphoblastic leukemia in China]. Zhonghua Er Ke Za Zhi; 2005 Dec;43(12):881-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [State of arts in therapy of childhood acute lymphoblastic leukemia in China].
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


34. Nishii K, Sakakura M, Tsukada T, Ryuu H, Katayama N: Successful treatment with imatinib combined with less intensive chemotherapy (vincristine and dexamethasone) as induction therapy in a very elderly patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol; 2007 Apr;85(3):273-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with imatinib combined with less intensive chemotherapy (vincristine and dexamethasone) as induction therapy in a very elderly patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Genes, abl / drug effects. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Hematol. 2004 Jan;79(1):79-84 [14979483.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):623-32 [12692601.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3507-12 [15315963.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2357-66 [12239143.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Leukemia. 2006 Mar;20(3):400-3 [16437142.001]
  • (PMID = 17483068.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


35. Han S, Lee KM, Park SK, Lee JE, Ahn HS, Shin HY, Kang HJ, Koo HH, Seo JJ, Choi JE, Ahn YO, Kang D: Genome-wide association study of childhood acute lymphoblastic leukemia in Korea. Leuk Res; 2010 Oct;34(10):1271-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide association study of childhood acute lymphoblastic leukemia in Korea.
  • We conducted a genome-wide association study of childhood acute lymphoblastic leukemia (ALL) in a case-control study conducted in Korea.
  • [MeSH-major] Genome-Wide Association Study. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • [CommentIn] Leuk Res. 2010 Oct;34(10):1269-70 [20538337.001]
  • (PMID = 20189245.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ARID5B protein, human; 0 / CCAAT-Enhancer-Binding Proteins; 0 / DNA-Binding Proteins; 0 / IKZF1 protein, human; 0 / Transcription Factors; 142805-41-2 / CEBPE protein, human; 148971-36-2 / Ikaros Transcription Factor
  •  go-up   go-down


36. Glass JO, Reddick WE, Li CS, Laningham FH, Helton KJ, Pui CH: Computer-aided detection of therapy-induced leukoencephalopathy in pediatric acute lymphoblastic leukemia patients treated with intravenous high-dose methotrexate. Magn Reson Imaging; 2006 Jul;24(6):785-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-aided detection of therapy-induced leukoencephalopathy in pediatric acute lymphoblastic leukemia patients treated with intravenous high-dose methotrexate.
  • The purpose of this study was to use objective quantitative magnetic resonance imaging (MRI) methods to develop a computer-aided detection (CAD) tool to differentiate white matter (WM) hyperintensities into either leukoencephalopathy (LE) induced by chemotherapy or normal maturational processes in children treated for acute lymphoblastic leukemia without irradiation.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 2000 Nov;35(5):456-61 [11070477.001]
  • [Cites] J Pediatr. 2001 Sep;139(3):413-20 [11562622.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1712-22 [9586883.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S124-6 [15124703.001]
  • [Cites] Radiology. 1991 Jul;180(1):205-9 [2052695.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):1997-2004 [1525778.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1993 May;15(2):231-8 [8498647.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):3-16 [9045302.001]
  • [Cites] Magn Reson Med. 2003 Oct;50(4):749-57 [14523961.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] Magn Reson Imaging. 2004 Apr;22(3):299-306 [15062925.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Jun-Jul;21(6):1099-109 [10871022.001]
  • [Cites] Radiology. 2003 Dec;229(3):659-69 [14576448.001]
  • [Cites] Hum Brain Mapp. 1999;7(4):254-66 [10408769.001]
  • [Cites] Magn Reson Med. 2004 Dec;52(6):1336-41 [15562471.001]
  • (PMID = 16824973.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090246-05; United States / NCI NIH HHS / CA / R01 CA090246; United States / NCI NIH HHS / CA / P30CA21765; United States / NCI NIH HHS / CA / R01CA90246; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / CA090246-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS49117; NLM/ PMC2396783
  •  go-up   go-down


37. Haroun HM, Mahfouz MS, Elhaj AM: Patterns of childhood cancer in children admitted to the institute of nuclear medicine, molecular biology and oncology (inmo), wad medani, gezira state. J Family Community Med; 2006 May;13(2):71-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patterns of childhood cancers in America and Europe are almost the same, with leukemia and central nervous system tumors accounting for over one-half of the new cases.
  • In contrast, lymphoma is the most common prevailing cancer of this age group in Africa.
  • RESULTS: The results showed a pattern of childhood lymphoma as the most common cancer (42.8%) followed by acute lymphoblastic leukemia (19.8%) and kidney tumor (12.8%).
  • CONCLUSION: Lymphoma, acute lymphoblastic leukemia and bone tumor commonly occurred in children above 5 years in contradistinction to kidney tumor and retinoblastoma which was prevalent in children less than 5 years of age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Pediatr (Phila). 1990 Feb;29(2):95-8 [2302907.001]
  • [Cites] Ann Trop Paediatr. 1989 Dec;9(4):261-5 [2482010.001]
  • [Cites] East Afr Med J. 2001 Jul;78(7):349-54 [11957257.001]
  • [Cites] Eur J Cancer Prev. 2004 Feb;13(1):47-51 [15075788.001]
  • [Cites] Neoplasma. 1989;36(2):233-43 [2716927.001]
  • [Cites] Arch Dis Child. 1995 Aug;73(2):100-4; discussion 104-5 [7574850.001]
  • [Cites] Ann Trop Paediatr. 2002 Jun;22(2):159-63 [12070951.001]
  • [Cites] East Afr Med J. 1995 Jan;72(1):25-9 [7781551.001]
  • [Cites] Afr J Med Med Sci. 1993 Mar;22(1):17-24 [7839877.001]
  • [Cites] West Afr J Med. 1995 Jul-Sep;14(3):174-80 [8519707.001]
  • [Cites] Am J Trop Med Hyg. 1996 Apr;54(4):343-7 [8615444.001]
  • [Cites] Int J Cancer. 2001 Feb 1;91(3):402-6 [11169966.001]
  • [Cites] Eur J Cancer. 1995;31A(5):771-82 [7640052.001]
  • (PMID = 23012108.001).
  • [ISSN] 1319-1683
  • [Journal-full-title] Journal of family & community medicine
  • [ISO-abbreviation] J Family Community Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3410067
  • [Keywords] NOTNLM ; Cancer / Leukemia / Lymphoma / Pattern / Prevalence
  •  go-up   go-down


38. Torpy JM, Lynm C, Glass RM: JAMA patient page. Acute lymphoblastic leukemia. JAMA; 2009 Jan 28;301(4):452
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JAMA patient page. Acute lymphoblastic leukemia.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19176449.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Patient Education Handout
  • [Publication-country] United States
  •  go-up   go-down


39. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, Prentice HG, Durrant J, Tallman MS, Goldstone AH, ECOG, MRC/NCRI Adult Leukemia Working Party: Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood; 2005 Dec 01;106(12):3760-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.
  • The international acute lymphoblastic leukemia (ALL) study was designed to prospectively define the optimal therapy for adults 60 years of age or younger with newly diagnosed ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


40. Hori T, Suzuki N, Mizue N, Hatakeyama N, Takamuro M, Tsutsumi H: Relapse of T-cell all after stem cell transplant presenting as hypertrophic cardiomyopathy: the value of non-invasive diagnostic imaging in detecting cardiac leukemia. Pediatr Blood Cancer; 2006 Jan;46(1):108-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse of T-cell all after stem cell transplant presenting as hypertrophic cardiomyopathy: the value of non-invasive diagnostic imaging in detecting cardiac leukemia.
  • We describe a 14-year-old female with acute lymphoblastic leukemia (ALL) with a mediastinal mass at diagnosis who developed hypertrophic cardiomyopathy (HC) after stem cell transplantation (SCT).
  • [MeSH-major] Cardiomyopathy, Hypertrophic / etiology. Diagnostic Imaging. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemic Infiltration. Myocardium / pathology


41. Ikai T, Miwa H, Shikami M, Hiramatsu A, Tajima E, Yamamoto H, Imai N, Hattori A, Nishii K, Miura K, Satoh A, Itoh M, Imamura A, Mihara H, Katoh Y, Nitta M: Placenta growth factor stimulates the growth of Philadelphia chromosome positive acute lymphoblastic leukemia cells by both autocrine and paracrine pathways. Eur J Haematol; 2005 Oct;75(4):273-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placenta growth factor stimulates the growth of Philadelphia chromosome positive acute lymphoblastic leukemia cells by both autocrine and paracrine pathways.
  • Vascular endothelial growth factor (VEGF) and its associated molecule, placenta growth factor (PlGF) are now known to support normal hematopoiesis, and leukemia cell growth.
  • In this study, expression of VEGF and PlGF in acute lymphoblastic leukemia (ALL) cells was examined by real time reverse transcription-polymerase chain reaction in 20 patient samples.
  • [MeSH-major] Autocrine Communication / physiology. Cell Proliferation. Paracrine Communication / physiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Pregnancy Proteins / physiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146532.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Pregnancy Proteins; 0 / RNA, Neoplasm; 0 / Vascular Endothelial Growth Factor A; 144589-93-5 / placenta growth factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


42. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM: Reprogramming of miRNA networks in cancer and leukemia. Genome Res; 2010 May;20(5):589-99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reprogramming of miRNA networks in cancer and leukemia.
  • Finally, we experimentally validated the miRNA network with acute lymphocytic leukemia originated in Mir155 transgenic mice.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Leukemia. MicroRNAs / genetics. Neoplasms
  • [MeSH-minor] Adenocarcinoma / metabolism. Animals. Cell Line, Tumor. Gene Dosage. Humans. Lung / metabolism. Lung Neoplasms / metabolism. Mice. Oligonucleotide Array Sequence Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


43. Bay A, Yilmaz C, Yilmaz N, Oner AF: Vincristine induced cranial polyneuropathy. Indian J Pediatr; 2006 Jun;73(6):531-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 5-year-old girl was diagnosed preB cell Acute Lymphoblastic Leukemia (ALL).
  • [MeSH-minor] Blepharoptosis / chemically induced. Blepharoptosis / drug therapy. Child, Preschool. Female. Humans. Ophthalmoplegia / chemically induced. Ophthalmoplegia / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyridostigmine Bromide / therapeutic use. Pyridoxine / therapeutic use

  • MedlinePlus Health Information. consumer health - B Vitamins.
  • Hazardous Substances Data Bank. PYRIDOSTIGMINE BROMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PYRIDOXINE HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacotherapy. 1998 Nov-Dec;18(6):1304-7 [9855331.001]
  • [Cites] Med Pediatr Oncol. 1996 Apr;26(4):280-3 [8600343.001]
  • [Cites] J Neurol. 2002 Jan;249(1):9-17 [11954874.001]
  • [Cites] Pediatr Blood Cancer. 2004 Mar;42(3):287-8 [14752870.001]
  • [Cites] Gastroenterology. 1980 Dec;79(6):1217-21 [7439629.001]
  • [Cites] Leukemia. 2003 Feb;17(2):328-33 [12592331.001]
  • [Cites] Ann Pharmacother. 2000 Oct;34(10):1136-8 [11054980.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Apr;25(4):316-20 [12679647.001]
  • [Cites] J Neurooncol. 1986;4(1):37-41 [3528407.001]
  • [Cites] Med Toxicol. 1986 Nov-Dec;1(6):421-7 [3540519.001]
  • (PMID = 16816519.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Cholinesterase Inhibitors; 12001-76-2 / Vitamin B Complex; 5J49Q6B70F / Vincristine; KV2JZ1BI6Z / Pyridoxine; KVI301NA53 / Pyridostigmine Bromide
  •  go-up   go-down


44. Sakhinia E, Faranghpour M, Liu Yin JA, Brady G, Hoyland JA, Byers RJ: Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow. Br J Haematol; 2005 Jul;130(2):233-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow.
  • Reverse transcription polymerase chain reaction (RT-PCR) measurement of Indicator genes for acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) was used to determine gene signatures.
  • The expression profile of the 17 top-ranked genes distinguishing AML and ALL were measured by RT-PCR in five ALL, 26 AML, 12 AML remission, four chronic myeloid leukaemia (CML) and nine morphologically normal BM samples.
  • [MeSH-major] Gene Expression Profiling / methods. Leukemia, Myeloid / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Adult. Antigens, CD34 / analysis. Bone Marrow Cells / metabolism. Cluster Analysis. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction / methods

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029452.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / DNA, Neoplasm
  •  go-up   go-down


45. Campbell MR, Nation PN, Andrew SE: A lack of DNA mismatch repair on an athymic murine background predisposes to hematologic malignancy. Cancer Res; 2005 Apr 1;65(7):2626-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, Msh2(-/-);Foxn1(nu/nu) and Msh6(-/-);Foxn1(nu/nu) mice developed primarily early-onset lymphoblastic lymphomas.
  • The development of hematologic malignancy in the mouse, even in the absence of a thymus, parallels the development of B- and T-cell lymphoma and leukemia in the few rare mismatch repair-null human patients that have been identified.
  • [MeSH-major] DNA Repair / genetics. DNA-Binding Proteins / deficiency. Lymphoma, B-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins / deficiency

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805259.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Forkhead Transcription Factors; 0 / Msh6 protein, mouse; 0 / Proto-Oncogene Proteins; 0 / Transcription Factors; 0 / Whn protein; EC 3.6.1.3 / Msh2 protein, mouse; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


46. Muzzafar T, Medeiros LJ, Wang SA, Brahmandam A, Thomas DA, Jorgensen JL: Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry. Am J Clin Pathol; 2009 Nov;132(5):692-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry.
  • We studied CD81 expression by flow cytometry (FC) on benign precursor B cells (hematogones) and leukemic blasts in precursor B-cell acute lymphoblastic leukemia (pre-B-ALL) and established its usefulness in minimal residual disease (MRD) assays.
  • [MeSH-major] Antigens, CD / biosynthesis. Biomarkers, Tumor / analysis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846809.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD81; 0 / Biomarkers, Tumor; 0 / CD81 protein, human
  •  go-up   go-down


47. Kawahara I, Masui K, Horie N, Matsuo T, Kitagawa N, Tsutsumi K, Nagata I, Morikawa M, Hayashi T: Radiation-induced meningioma following prophylactic radiotherapy for acute lymphoblastic leukemia in childhood. Pediatr Neurosurg; 2007;43(1):36-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced meningioma following prophylactic radiotherapy for acute lymphoblastic leukemia in childhood.
  • BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / etiology. Meningioma / diagnosis. Meningioma / etiology. Neoplasms, Radiation-Induced / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy


48. Medyouf H, Gao X, Armstrong F, Gusscott S, Liu Q, Gedman AL, Matherly LH, Schultz KR, Pflumio F, You MJ, Weng AP: Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood; 2010 Feb 11;115(6):1175-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NOTCH1 is activated by mutation in more than 50% of human T-cell acute lymphoblastic leukemias (T-ALLs) and inhibition of Notch signaling causes cell-cycle/growth arrest, providing rationale for NOTCH1 as a therapeutic target.
  • Furthermore, we noted in the mouse model that Pten loss accelerated disease onset and produced multiclonal tumors, suggesting NOTCH1 activation and Pten loss may collaborate in leukemia induction.

  • Jackson Laboratory JAX®Mice Database. culture/stock collections - NOD.Cg-Prkdc<scid> Il2rg<tm1Wjl>/SzJ (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2008 May 8;453(7192):228-32 [18418377.001]
  • [Cites] Curr Protoc Immunol. 2007 Aug;Chapter 8:Unit 8.17 [18432997.001]
  • [Cites] J Clin Invest. 2008 Sep;118(9):3181-94 [18677410.001]
  • [Cites] Oncogene. 2008 Sep 18;27(41):5497-510 [18794884.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1129-33 [18948956.001]
  • [Cites] J Clin Invest. 2008 Nov;118(11):3762-74 [18830414.001]
  • [Cites] Nat Med. 2009 Jan;15(1):50-8 [19098907.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1730-40 [18984862.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6172-81 [19246562.001]
  • [Cites] Gene Ther. 2000 Jun;7(12):1063-6 [10871756.001]
  • [Cites] Br J Pharmacol. 2009 Nov;158(5):1183-95 [19775282.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4508-13 [11917122.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):655-64 [12509463.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1784-9 [12411302.001]
  • [Cites] Nature. 2003 May 15;423(6937):302-5 [12714971.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2492-8 [15198948.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 1995 Feb 1;85(3):854 [7833489.001]
  • [Cites] Science. 1995 Sep 8;269(5229):1427-9 [7660125.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):348-55 [9697695.001]
  • [Cites] Curr Biol. 1998 Oct 22;8(21):1169-78 [9799734.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1563-8 [9990064.001]
  • [Cites] Oncogene. 1999 Mar 4;18(9):1765-9 [10208437.001]
  • [Cites] Annu Rev Immunol. 2005;23:945-74 [15771590.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Nature. 2006 May 25;441(7092):475-82 [16598206.001]
  • [Cites] Nature. 2006 May 25;441(7092):518-22 [16633340.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4642-51 [16738328.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(16):6261-71 [16880534.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8022-31 [16954387.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3579-87 [17213287.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5463-72 [17317856.001]
  • [Cites] Nat Med. 2007 Jun;13(6):736-41 [17515895.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] PLoS One. 2007;2(11):e1237 [18043744.001]
  • [Cites] Curr Protoc Mol Biol. 2001 Nov;Chapter 15:Unit 15.3 [18265117.001]
  • [Cites] Annu Rev Pathol. 2008;3:587-613 [18039126.001]
  • [Cites] Haematologica. 2008 Apr;93(4):533-42 [18322257.001]
  • [Cites] Nature. 2008 May 22;453(7194):529-33 [18463637.001]
  • (PMID = 20008304.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K22 CA112538; United States / NCI NIH HHS / CA / R01 CA076641; United States / NCI NIH HHS / CA / T32 CA009531; United States / NCI NIH HHS / CA / CA76641
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn2a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Enzyme Inhibitors; 0 / Il2rg protein, mouse; 0 / Interleukin Receptor Common gamma Subunit; 0 / RNA, Messenger; 0 / Receptor, Notch1; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.4.- / Amyloid Precursor Protein Secretases
  • [Other-IDs] NLM/ PMC2826229
  •  go-up   go-down


49. Gao YJ, Lu FJ, Wang HS: Treating childhood acute lymphoblastic leukemia in a developing country 1998-2003: the experience of a single children's hospital in China. J Pediatr Hematol Oncol; 2006 Dec;28(12):798-802
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating childhood acute lymphoblastic leukemia in a developing country 1998-2003: the experience of a single children's hospital in China.
  • PURPOSE: To assess the outcome of children with acute lymphoblastic leukemia (ALL) treating with ALL China-98 in a single children's Hospital in China.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality


50. Lefèvre Y, Ceroni D, Läedermann A, de Rosa V, de Coulon G, Ayse HO, Kaelin A: Pediatric leukemia revealed by a limping episode: a report of four cases. Orthop Traumatol Surg Res; 2009 Feb;95(1):77-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric leukemia revealed by a limping episode: a report of four cases.
  • Acute leukemia is a rarely encountered disease in the orthopedic surgeon's activity.
  • We report our experience with four cases of children initially seen in the pediatric emergency department for limping, as their revealing presentation of acute leukemia.
  • The physician in charge should remember that paraclinical work-up normal results do not exclude a diagnosis of acute leukemia, that any drop in hematopoietic cell counts should call for a myelogram and that paraclinical exams, including the hemogram, should be repeated until a diagnosis and improvement or confirmed cure is achieved over time.
  • [MeSH-major] Mobility Limitation. Pain / etiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251241.001).
  • [ISSN] 1877-0568
  • [Journal-full-title] Orthopaedics & traumatology, surgery & research : OTSR
  • [ISO-abbreviation] Orthop Traumatol Surg Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [General-notes] NLM/ Original DateCompleted: 20090708
  •  go-up   go-down


51. Gluckman E, Rocha V, EBMT Paediatric, Acute Leukemia Working Parties, Eurocord: Indications and results of cord blood transplant in children with leukemia. Bone Marrow Transplant; 2008 Jun;41 Suppl 2:S80-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indications and results of cord blood transplant in children with leukemia.
  • The literature shows that after UCBT relapse rate (RR), disease-free survival and overall survival of children with acute leukemia are similar to other hematopoietic stem cell sources (matched unrelated BM).
  • In conclusion, UCB is a valuable alternative source of hematopoietic stem cell transplantation in children with acute leukemia who need an allogeneic transplant, but lack a suitable sibling donor.
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18545251.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


52. Stano-Kozubik K, Malcikova J, Tichy B, Kotaskova J, Borsky M, Hrabcakova V, Francova H, Valaskova I, Bourkova L, Smardova J, Doubek M, Brychtova Y, Pospisilova S, Mayer J, Trbusek M: Inactivation of p53 and amplification of MYCN gene in a terminal lymphoblastic relapse in a chronic lymphocytic leukemia patient. Cancer Genet Cytogenet; 2009 Feb;189(1):53-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of p53 and amplification of MYCN gene in a terminal lymphoblastic relapse in a chronic lymphocytic leukemia patient.
  • B-cell chronic lymphocytic leukemia (CLL) is an incurable disease with a highly variable clinical course.
  • A recent association has been observed between the presence of aberrant somatic hypermutations in leukemic cells (hypermutations occurring outside of the immunoglobulin locus) and the transformation to a diffuse large B-cell lymphoma or prolymphocytic leukemia.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Nuclear Proteins / genetics. Oncogene Proteins / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19167613.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYCN protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


53. Kuzmanovic M, Rasovic N, Micic D, Bunjevacki G, Cupic V, Pasic S: Epstein-Barr virus associated hemophagocytic lymphohystiocytosis during maintenance treatment of acute lymphoblastic leukemia. Pediatr Blood Cancer; 2006 Jun;46(7):832
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus associated hemophagocytic lymphohystiocytosis during maintenance treatment of acute lymphoblastic leukemia.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Lymphohistiocytosis, Hemophagocytic / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16435378.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


54. Koschmann C, Thomson B, Hawkins DS: No evidence of a trial effect in newly diagnosed pediatric acute lymphoblastic leukemia. Arch Pediatr Adolesc Med; 2010 Mar;164(3):214-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No evidence of a trial effect in newly diagnosed pediatric acute lymphoblastic leukemia.
  • PARTICIPANTS: Data were drawn from 322 patients with newly diagnosed acute lymphoblastic leukemia.
  • (1) Demographic variables associated with trial participation. (2) Event-free survival, which was defined as the time from initial diagnosis to either leukemia recurrence or death from any cause.
  • CONCLUSIONS: Clinical trial participation does not, by itself, lead to improved outcome for pediatric patients with acute lymphoblastic leukemia in the current era.
  • [MeSH-major] Clinical Trials as Topic. Health Knowledge, Attitudes, Practice. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Pediatr Adolesc Med. 2010 Mar;164(3):293-4 [20194266.001]
  • [CommentIn] Arch Pediatr Adolesc Med. 2010 Sep;164(9):882; author reply 882-3 [20819974.001]
  • (PMID = 20194252.001).
  • [ISSN] 1538-3628
  • [Journal-full-title] Archives of pediatrics & adolescent medicine
  • [ISO-abbreviation] Arch Pediatr Adolesc Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Zuurbier L, Homminga I, Calvert V, te Winkel ML, Buijs-Gladdines JG, Kooi C, Smits WK, Sonneveld E, Veerman AJ, Kamps WA, Horstmann M, Petricoin EF 3rd, Pieters R, Meijerink JP: NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia; 2010 Dec;24(12):2014-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols.
  • Aberrant activation of the NOTCH1 pathway by inactivating and activating mutations in NOTCH1 or FBXW7 is a frequent phenomenon in T-cell acute lymphoblastic leukemia (T-ALL).
  • We retrospectively investigated the relevance of NOTCH1/FBXW7 mutations for pediatric T-ALL patients enrolled on Dutch Childhood Oncology Group (DCOG) ALL7/8 or ALL9 or the German Co-Operative Study Group for Childhood Acute Lymphoblastic Leukemia study (COALL-97) protocols.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Prednisone / therapeutic use. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2010 Dec;24(12):2003-4 [21157484.001]
  • (PMID = 20861909.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / Homeodomain Proteins; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; 0 / TLX3 protein, human; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases; VB0R961HZT / Prednisone
  •  go-up   go-down


56. Pelissari DM, Barbieri FE, Wünsch Filho V: Magnetic fields and acute lymphoblastic leukemia in children: a systematic review of case-control studies. Cad Saude Publica; 2009;25 Suppl 3:S441-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic fields and acute lymphoblastic leukemia in children: a systematic review of case-control studies.
  • Leukemia incidence in children has increased worldwide in recent decades, particularly due to the rise in acute lymphoblastic leukemia.
  • Studies have associated exposure to non-ionizing radiation generated by low frequency magnetic fields with childhood leukemia.
  • An association may exist between exposure to low frequency magnetic fields and acute lymphoblastic leukemia in children, but this association is weak, preventing the observation of consistency in the findings.
  • Future studies from a wider range of geographic regions should focus on the analysis of acute lymphoblastic leukemia, which is the subtype with the greatest impact on the increasing overall incidence of childhood leukemia.
  • [MeSH-major] Electromagnetic Fields / adverse effects. Environmental Exposure / adverse effects. Leukemia, Radiation-Induced / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology


57. Balduzzi A, De Lorenzo P, Schrauder A, Conter V, Uderzo C, Peters C, Klingebiel T, Stary J, Felice MS, Magyarosy E, Schrappe M, Dini G, Gadner H, Valsecchi MG: Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time. Haematologica; 2008 Jun;93(6):925-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time.
  • The advantage of allogeneic transplant from compatible related donors versus chemotherapy in children with very-high-risk acute lymphoblastic leukemia in first complete remission was previously demonstrated in an international prospective trial.
  • Of 357 pediatric patients with very-high-risk acute lymphoblastic leukemia, 259 received chemotherapy, 55 transplantation from compatible related and 43 from unrelated donors.
  • The relative advantage of transplant from compatible related donors in very-high-risk childhood acute lymphoblastic leukemia was consistent for any time elapsed in first remission.
  • [MeSH-major] Bone Marrow Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Homologous / methods


58. Ataergin S, Kanat O, Arpaci F, Ozet A: A rare occurrence of diffuse lymphoblastic lymphoma in pregnancy. Am J Hematol; 2007 Feb;82(2):173-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare occurrence of diffuse lymphoblastic lymphoma in pregnancy.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma. Pregnancy Complications


59. Frassoni F, Gualandi F, Podestà M, Raiola AM, Ibatici A, Piaggio G, Sessarego M, Sessarego N, Gobbi M, Sacchi N, Labopin M, Bacigalupo A: Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol; 2008 Sep;9(9):831-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study.
  • METHODS: Adult patients with acute leukaemia, for whom an unrelated stem-cell transplantation was indicated and no suitable unrelated human leucocyte antigen (HLA)-matched donor had been identified, were included in the study and underwent a cord-blood transplant in San Martino Hospital, Genoa, Italy.
  • FINDINGS: Between March 31, 2006, and Jan 25, 2008, 32 consecutive patients with acute myeloid leukaemia (n=20) or acute lymphoblastic leukaemia (n=12) underwent a cord-blood transplant (median age 36 years [range 18-66]).
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


60. Heesch S, Goekbuget N, Stroux A, Tanchez JO, Schlee C, Burmeister T, Schwartz S, Blau O, Keilholz U, Busse A, Hoelzer D, Thiel E, Hofmann WK, Baldus CD: Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. Haematologica; 2010 Jun;95(6):942-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.
  • BACKGROUND: The role of the Wilms tumor 1 gene (WT1) in acute leukemias has been underscored by mutations found in acute myeloid leukemia identifying patients with inferior survival.
  • Furthermore, aberrant expression of WT1 in acute myeloid leukemia was associated with an increased risk of relapse.
  • No larger studies have performed a combined approach including WT1 mutation and expression analyses in acute T-lymphoblastic leukemia.
  • DESIGN AND METHODS: We analyzed the WT1 mutations and the expression status in a total of 252 consecutive adult patients with newly diagnosed T-lymphoblastic leukemia, who were registered on the GMALL 06/99 and 07/03 protocols and had sufficient material available.
  • The GMALL protocols included intensive chemotherapy as well as stem cell transplantation according to a risk-based model with indication for stem cell transplantation in first complete remission for early and mature T-lymphoblastic leukemia patients; patients with thymic T-lymphoblastic leukemia were allocated to a standard risk group and treated with intensive chemotherapy.
  • In thymic T-lymphoblastic leukemia, WT1mut patients had an inferior relapse-free survival compared to WT1 wild-type patients.
  • T-lymphoblastic leukemia patients with aberrant WT1 expression (high or negative) showed a higher relapse rate and an inferior outcome compared to patients with intermediate WT1 expression.
  • In the standard risk group of thymic T-lymphoblastic leukemia, aberrant WT1 expression was predictive for an inferior relapse-free survival as compared to patients with intermediate expression.
  • CONCLUSIONS: WT1 mutations were associated with an inferior relapse-free survival in standard risk thymic T-lymphoblastic leukemia patients.
  • Moreover, altered expression associated with inferior outcome also suggests a role of WT1 in T-lymphoblastic leukemia and the potential use of molecularly-based treatment stratification to improve outcome.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Genes, Wilms Tumor / physiology. Mutation / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Leukemia. 1995 Jun;9(6):1060-7 [7596170.001]
  • [Cites] Exp Hematol. 1997 Apr;25(4):312-20 [9131006.001]
  • [Cites] Leukemia. 1997 May;11(5):639-43 [9180285.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1217-25 [9242555.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2961-8 [9531607.001]
  • [Cites] EMBO J. 1999 Jul 15;18(14):3990-4003 [10406804.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:80-97 [15561678.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1416-23 [15920493.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4414-5 [16326981.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Leukemia. 2006 Feb;20(2):254-63 [16341043.001]
  • [Cites] Haematologica. 2006 Feb;91(2):270-1 [16461320.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1507-15 [16575000.001]
  • [Cites] Oncogene. 2006 Jul 13;25(30):4217-29 [16518414.001]
  • [Cites] Leukemia. 2007 Mar;21(3):550-1; author reply 552 [17205055.001]
  • [Cites] Leukemia. 2007 May;21(5):868-76 [17361230.001]
  • [Cites] Expert Rev Mol Med. 2007;9(14):1-17 [17524167.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Leukemia. 2008 Apr;22(4):762-70 [18185524.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1154-60 [18368072.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]
  • [Cites] Blood. 2009 Jul 30;114(5):1038-45 [19494353.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3303-12 [16380455.001]
  • [Cites] EMBO J. 2001 Apr 17;20(8):1897-909 [11296223.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1914-22 [11753613.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):409-20 [11841446.001]
  • [Cites] Int J Hematol. 2003 Jun;77(5):463-70 [12841384.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1589-95 [12886247.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2474-86 [14562124.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Blood. 2004 Jul 15;104(2):558-60 [15044257.001]
  • [Cites] Haematologica. 2004 Aug;89(8):926-33 [15339675.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 1989 Apr;73(5):1247-58 [2467704.001]
  • [Cites] J Biol Chem. 1994 Feb 25;269(8):6198-206 [8119964.001]
  • [Cites] Hum Mutat. 1997;9(3):209-25 [9090524.001]
  • (PMID = 20435628.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2878792
  •  go-up   go-down


61. Lipshultz SE: Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol; 2006 Jun;33(3 Suppl 8):S8-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of anthracyclines in the treatment of acute lymphoblastic leukemia is limited by associated cardiotoxic effects, which can result in cardiomyopathy and congestive heart failure, and may be irreversible.
  • A study of the efficacy of dexrazoxane in reducing doxorubicin-induced cardiotoxicity in children and adolescents with high-risk acute lymphoblastic leukemia, showed that significantly fewer dexrazoxane-treated patients (21%) had elevated serum cardiac troponin (a biomarker of acute myocardial injury) levels than patients treated with chemotherapy alone (50%; P <.001).
  • [MeSH-minor] Adolescent. Adult. Cardiovascular Agents / therapeutic use. Child. Disease Progression. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Razoxane / therapeutic use. Risk Factors. Survivors

  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16781284.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents; 0 / Cardiovascular Agents; 5AR83PR647 / Razoxane
  • [Number-of-references] 50
  •  go-up   go-down


62. Ludajic K, Balavarca Y, Bickeböller H, Pohlreich D, Kouba M, Dobrovolna M, Vrana M, Rosenmayr A, Fischer GF, Fae I, Kalhs P, Greinix HT: Impact of HLA-DPB1 allelic and single amino acid mismatches on HSCT. Br J Haematol; 2008 Jul;142(3):436-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Amino Acids / genetics. HLA-DP Antigens / genetics. Hematopoietic Stem Cell Transplantation. Leukemia / therapy. Polymorphism, Genetic
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Alleles. Chronic Disease. Female. Follow-Up Studies. Gene Frequency. Graft vs Host Disease. HLA-DP beta-Chains. Histocompatibility Testing / methods. Humans. Leukemia, Myeloid / immunology. Leukemia, Myeloid / mortality. Leukemia, Myeloid / therapy. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18544086.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acids; 0 / HLA-DP Antigens; 0 / HLA-DP beta-Chains; 0 / HLA-DPB1 antigen
  •  go-up   go-down


63. Korycka A, Lech-Marańda E, Robak T: Novel purine nucleoside analogues for hematological malignancies. Recent Pat Anticancer Drug Discov; 2008 Jun;3(2):123-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, all these drugs have demonstrated promising activity in patients with relapsed and refractory acute lymphoblastic leukemia (ALL).
  • Moreover, the drug exhibits an efficacy in acute myeloid leukemia (AML), blast crisis of chronic myelogenous leukemia (CML-BP) and myelodysplastic syndrome (MDS).
  • Nelarabine is recommended for T-ALL and T-cell lymphoblastic lymphoma (T-LBL) with the overall response rates ranging from 11 to 60%.
  • Forodesine is a purine nucleoside phosphorylase (PNP) inhibitor and it has shown activity in relapsed and refractory T- and B-cells leukemias as well as in cutaneous T-cell lymphoma (CTCL).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537755.001).
  • [ISSN] 1574-8928
  • [Journal-full-title] Recent patents on anti-cancer drug discovery
  • [ISO-abbreviation] Recent Pat Anticancer Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 0 / Purine Nucleosides; 0 / Pyrimidinones; 426X066ELK / forodesine; 60158CV180 / nelarabine; 762RDY0Y2H / clofarabine
  • [Number-of-references] 102
  •  go-up   go-down


64. Kleppe M, Lahortiga I, El Chaar T, De Keersmaecker K, Mentens N, Graux C, Van Roosbroeck K, Ferrando AA, Langerak AW, Meijerink JP, Sigaux F, Haferlach T, Wlodarska I, Vandenberghe P, Soulier J, Cools J: Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet; 2010 Jun;42(6):530-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.
  • In this work, we describe the identification of focal deletions of PTPN2 in human T-cell acute lymphoblastic leukemia (T-ALL).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2429-37 [8139546.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):499-503 [1731319.001]
  • [Cites] J Cell Biol. 1995 Nov;131(3):631-43 [7593185.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1680-5 [9050838.001]
  • [Cites] J Biol Chem. 1997 Aug 22;272(34):21548-57 [9261175.001]
  • [Cites] Methods. 2005 Jan;35(1):44-53 [15588985.001]
  • [Cites] Nat Immunol. 2005 Mar;6(3):253-60 [15696169.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4849-52 [15713800.001]
  • [Cites] J Exp Med. 2005 Jun 6;201(11):1715-23 [15928199.001]
  • [Cites] Blood. 2005 Jul 1;106(1):274-86 [15774621.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1116-27 [16079112.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(6):2166-79 [17210636.001]
  • [Cites] Nat Genet. 2007 May;39(5):593-5 [17435759.001]
  • [Cites] Nature. 2007 Jun 7;447(7145):661-78 [17554300.001]
  • [Cites] Nat Genet. 2007 Jul;39(7):857-64 [17554260.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1251-61 [17452517.001]
  • [Cites] Haematologica. 2008 Apr;93(4):533-42 [18322257.001]
  • [Cites] J Exp Med. 2008 Apr 14;205(4):751-8 [18362173.001]
  • [Cites] Nat Rev Immunol. 2008 May;8(5):380-90 [18421304.001]
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] Mol Cell. 2008 Jul 11;31(1):134-42 [18614052.001]
  • [Cites] Cancer Cell. 2008 Aug 12;14(2):166-79 [18691551.001]
  • [Cites] Immunol Rev. 2009 Mar;228(1):325-41 [19290937.001]
  • [Cites] Nat Rev Immunol. 2001 Dec;1(3):200-8 [11905829.001]
  • [Cites] Curr Biol. 2002 Mar 19;12(6):446-53 [11909529.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(16):5662-8 [12138178.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • (PMID = 20473312.001).
  • [ISSN] 1546-1718
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] ENG
  • [Databank-accession-numbers] RefSeq/ NM/ 002828/ NM/ 008977/ NM/ 080422/ NM/ 080423
  • [Grant] United States / NCI NIH HHS / CA / R01 CA120196-01A1; United States / NCI NIH HHS / CA / R01 CA129382; United States / NCI NIH HHS / CA / CA129382; United States / NCI NIH HHS / CA / CA120196; United States / NCI NIH HHS / CA / R01 CA120196; United States / NCI NIH HHS / CA / CA120196-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Chemokine CCL1; 0 / Homeodomain Proteins; 0 / Interleukin-2; 0 / Interleukin-7; 0 / Piperazines; 0 / Proto-Oncogene Proteins; 0 / Pyrimidines; 143275-75-6 / TLX1 protein, human; 8A1O1M485B / Imatinib Mesylate; EC 3.1.3.48 / PTPN2 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 2
  • [Other-IDs] NLM/ NIHMS239727; NLM/ PMC2957655
  •  go-up   go-down


65. Oh SH, Park TS, Choi JR, Lee S, Cho SY, Kim SY, Kim J, Park JK, Song SA, Lee JY, Shin JH, Kim HR, Lee JN: Two childhood cases of acute leukemia with t(16;21)(p11.2;q22): second case report of infantile acute lymphoblastic leukemia with unusual type of FUS-ERG chimeric transcript. Cancer Genet Cytogenet; 2010 Jul 15;200(2):180-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two childhood cases of acute leukemia with t(16;21)(p11.2;q22): second case report of infantile acute lymphoblastic leukemia with unusual type of FUS-ERG chimeric transcript.
  • We report two childhood cases of acute leukemia with t(16;21)(p11.2;q22) and FUS-ERG rearrangements.
  • Patient 1 (14 years old) was initially diagnosed with acute myeloid leukemia.
  • Patient 2 (8 months old) was diagnosed with acute lymphoblastic leukemia (ALL) on the basis of bone marrow morphology and immunophenotyping.
  • [MeSH-major] Chromosomes, Human, Pair 16. Chromosomes, Human, Pair 21. Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. RNA, Messenger / analysis. RNA-Binding Protein FUS / genetics. Translocation, Genetic


66. Ashworth TD, Pear WS, Chiang MY, Blacklow SC, Mastio J, Xu L, Kelliher M, Kastner P, Chan S, Aster JC: Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood; 2010 Dec 16;116(25):5455-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Point mutations that trigger ligand-independent proteolysis of the Notch1 ectodomain occur frequently in human T-cell acute lymphoblastic leukemia (T-ALL) but are rare in murine T-ALL, suggesting that other mechanisms account for Notch1 activation in murine tumors.
  • [MeSH-major] Homeodomain Proteins / physiology. Peptide Chain Initiation, Translational / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Promoter Regions, Genetic / genetics. Receptor, Notch1 / genetics. Transcriptional Activation / physiology

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2002 Jun 28;109(7):811-21 [12110179.001]
  • [Cites] Radiat Res. 2002 Mar;157(3):331-40 [11839096.001]
  • [Cites] Nat Immunol. 2003 Feb;4(2):168-74 [12514733.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):551-64 [12842084.001]
  • [Cites] Carcinogenesis. 2003 Jul;24(7):1257-68 [12807718.001]
  • [Cites] Science. 2003 Aug 22;301(5636):1096-9 [12934008.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1683-8 [8643690.001]
  • [Cites] Genes Dev. 1996 Aug 1;10(15):1930-44 [8756350.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3780-92 [9808572.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8882-90 [15604248.001]
  • [Cites] Nature. 2005 Jul 14;436(7048):221-6 [16015321.001]
  • [Cites] Cell. 2005 Aug 12;122(3):435-47 [16096062.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3898-906 [16118316.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):209-20 [16354692.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4642-51 [16738328.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(11):3831-42 [10805726.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7505-15 [11003647.001]
  • [Cites] Mol Cell. 2000 Oct;6(4):939-45 [11090631.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1279-87 [16688224.001]
  • [Cites] Nat Struct Mol Biol. 2007 Apr;14(4):295-300 [17401372.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):404-8 [17621273.001]
  • [Cites] J Biol Chem. 2008 Mar 21;283(12):8046-54 [18182388.001]
  • [Cites] Annu Rev Pathol. 2008;3:587-613 [18039126.001]
  • [Cites] J Clin Invest. 2008 Sep;118(9):3181-94 [18677410.001]
  • [Cites] Immunity. 2009 Jan 16;30(1):67-79 [19110448.001]
  • [Cites] Mutat Res. 2009 Jan 15;660(1-2):22-32 [19000702.001]
  • [Cites] Cell. 2009 Apr 17;137(2):216-33 [19379690.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4381-90 [19075186.001]
  • [Cites] J Biol Chem. 2009 May 8;284(19):13013-22 [19254953.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6172-81 [19246562.001]
  • [Cites] Genes Dev. 2009 Jul 15;23(14):1665-76 [19605688.001]
  • [Cites] Mol Cell Biol. 2009 Nov;29(21):5679-95 [19704010.001]
  • [Cites] Nature. 2009 Nov 12;462(7270):182-8 [19907488.001]
  • [Cites] J Neurosci. 2010 Feb 3;30(5):1648-56 [20130175.001]
  • [Cites] PLoS One. 2010;5(2):e9094 [20161710.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5106-11 [20194733.001]
  • [Cites] Cell. 2010 Apr 30;141(3):419-31 [20398922.001]
  • [Cites] Blood. 2010 Dec 16;116(25):5443-54 [20829372.001]
  • [CommentIn] Blood. 2010 Dec 16;116(25):5436-8 [21163932.001]
  • (PMID = 20852131.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096899
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Notch1 protein, mouse; 0 / RNA, Messenger; 0 / Receptor, Notch1; 0 / Zfpn1a1 protein, mouse; 128559-51-3 / RAG-1 protein; 148971-36-2 / Ikaros Transcription Factor
  • [Other-IDs] NLM/ PMC3031398
  •  go-up   go-down


67. Zalewska-Szewczyk B, Matusiak I, Wyka K, Trelińska J, Stolarska M, Młynarski W: [Changes in the lipid profile in children with acute lymphoblastic leukaemia - the influence of the disease and its treatment]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1035-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes in the lipid profile in children with acute lymphoblastic leukaemia - the influence of the disease and its treatment].
  • The aim of the study was a prospective evaluation of the lipid profile in children with acute lymphoblastic leukaemia, before and during the treatment with L-asparaginase.
  • [MeSH-major] Asparaginase / therapeutic use. Lipid Metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531822.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cholesterol, HDL; 0 / Cholesterol, LDL; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


68. Ogbomo H, Michaelis M, Klassert D, Doerr HW, Cinatl J Jr: Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells. Neoplasia; 2008 Dec;10(12):1402-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, the sensitivity of cytarabine (1-beta-D-arabinofuranosylcytosine, araC)-resistant and parental human leukemic cell lines (T-lymphoid H9 and acute T-lymphoblastic leukemia Molt-4) to natural killer (NK) cell-mediated killing was investigated.
  • [MeSH-major] Cytarabine / pharmacology. Drug Resistance, Neoplasm. Killer Cells, Natural / metabolism. Leukemia / drug therapy. Leukemia / metabolism. NK Cell Lectin-Like Receptor Subfamily K / biosynthesis. Up-Regulation

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Immunol. 2003 Jun;4(6):557-64 [12740575.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1389-96 [12714493.001]
  • [Cites] J Exp Med. 2003 Aug 18;198(4):557-67 [12913096.001]
  • [Cites] Eur J Cancer. 2003 Oct;39(15):2142-9 [14522371.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):78-85 [14618619.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):216-25 [14993903.001]
  • [Cites] Int Immunol. 2004 Apr;16(4):533-8 [15039383.001]
  • [Cites] Int J Cancer. 2004 Sep 10;111(4):484-93 [15239124.001]
  • [Cites] Cancer Res. 1969 Feb;29(2):459-63 [5250069.001]
  • [Cites] Nat New Biol. 1971 Sep 22;233(38):109-10 [5285962.001]
  • [Cites] Klin Padiatr. 1999 Jul-Aug;211(4):239-44 [10472557.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1800-7 [15505620.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9180-4 [15604290.001]
  • [Cites] Leukemia. 2005 Apr;19(4):586-94 [15703783.001]
  • [Cites] Br J Haematol. 2005 Jun;129(5):677-86 [15916691.001]
  • [Cites] Biochem Pharmacol. 2005 Aug 1;70(3):426-32 [15950950.001]
  • [Cites] J Immunol. 2005 Jul 15;175(2):720-9 [16002667.001]
  • [Cites] Cancer Treat Rep. 1977 Sep;61(6):1109-16 [332346.001]
  • [Cites] Cancer Res. 1979 Jan;39(1):42-9 [282940.001]
  • [Cites] J Clin Invest. 1982 Feb;69(2):479-89 [6948829.001]
  • [Cites] JAMA. 1982 Nov 19;248(19):2481-6 [6957624.001]
  • [Cites] Semin Oncol. 1992 Dec;19(6):695-706 [1361080.001]
  • [Cites] Blood. 1996 Jan 1;87(1):256-64 [8547650.001]
  • [Cites] Nat Med. 1996 May;2(5):574-7 [8616718.001]
  • [Cites] Immunity. 1996 Jun;4(6):573-81 [8673704.001]
  • [Cites] J Natl Cancer Inst. 1997 Jun 4;89(11):750-1 [9182966.001]
  • [Cites] J Natl Cancer Inst. 1997 Jun 4;89(11):783-9 [9182976.001]
  • [Cites] Leukemia. 1997 Nov;11(11):1833-41 [9369415.001]
  • [Cites] Anticancer Drugs. 1998 Feb;9(2):105-23 [9510496.001]
  • [Cites] Eur J Cancer. 1998 Feb;34(3):296-306 [9640213.001]
  • [Cites] Leukemia. 1999 Mar;13(3):400-9 [10086731.001]
  • [Cites] Leukemia. 1999 Mar;13(3):410-8 [10086732.001]
  • [Cites] Science. 1999 Jul 30;285(5428):727-9 [10426993.001]
  • [Cites] Nucleosides Nucleotides. 1999 Apr-May;18(4-5):921-6 [10432710.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1711-7 [15886320.001]
  • [Cites] Nat Immunol. 2005 Sep;6(9):928-37 [16116470.001]
  • [Cites] Immunol Lett. 2005 Aug 15;100(1):7-13 [16109445.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jan 6;339(1):375-9 [16297863.001]
  • [Cites] Br J Cancer. 2005 Dec 12;93(12):1388-94 [16333246.001]
  • [Cites] J Immunol. 2006 Apr 15;176(8):5108-16 [16585609.001]
  • [Cites] Leukemia. 2006 Jan;20(1):151-4 [16307021.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Aug;291(2):L222-31 [16473864.001]
  • [Cites] Ann Hematol. 2006 Oct;85(10):717-22 [16832677.001]
  • [Cites] Eur J Haematol. 2006 Oct;77(4):293-9 [16856922.001]
  • [Cites] Neoplasia. 2006 Oct;8(10):807-16 [17032497.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):771-9 [17256136.001]
  • [Cites] Neoplasia. 2007 Sep;9(9):723-33 [17898868.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2349-57 [18381442.001]
  • [Cites] Br J Haematol. 1974 May;27(1):39-46 [4368900.001]
  • [Cites] Immunity. 2001 Feb;14(2):123-33 [11239445.001]
  • [Cites] Nat Immunol. 2001 Mar;2(3):255-60 [11224526.001]
  • [Cites] Eur J Immunol. 2001 Apr;31(4):1076-86 [11298332.001]
  • [Cites] Nat Immunol. 2000 Aug;1(2):119-26 [11248803.001]
  • [Cites] Eur J Immunol. 2001 May;31(5):1428-37 [11465099.001]
  • [Cites] Nature. 2001 Sep 13;413(6852):165-71 [11557981.001]
  • [Cites] Curr Med Chem. 2001 Nov;8(13):1543-72 [11562282.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):1433-7 [11563038.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1178-80 [11689875.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1892-7 [11753610.001]
  • [Cites] J Immunol. 2002 Jan 15;168(2):671-9 [11777960.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):41-9 [11905813.001]
  • [Cites] Curr Opin Immunol. 2002 Jun;14(3):306-11 [11973127.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6178-86 [12414645.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):36-43 [12532417.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):391-409 [12688309.001]
  • [Cites] Haematologica. 2003 May;88(5):509-21 [12745270.001]
  • (PMID = 19048119.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / KLRK1 protein, human; 0 / Ligands; 0 / NK Cell Lectin-Like Receptor Subfamily K; 04079A1RDZ / Cytarabine; 82115-62-6 / Interferon-gamma; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ PMC2586691
  •  go-up   go-down


69. Rameshwar P: Is substance P central to the biology of acute lymphoblastic leukemia? Leuk Res; 2008 Jan;32(1):3-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is substance P central to the biology of acute lymphoblastic leukemia?
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Substance P / physiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Leuk Res. 2008 Jan;32(1):97-102 [17588657.001]
  • (PMID = 17618685.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-1beta; 33507-63-0 / Substance P
  •  go-up   go-down


70. Cheng H, Hwang I, Chong Y, Tavassoli A, Webb ME, Zhang Y, Wilson IA, Benkovic SJ, Boger DL: Synthesis and biological evaluation of N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid as a potential inhibitor of GAR Tfase and the de novo purine biosynthetic pathway. Bioorg Med Chem; 2005 May 16;13(10):3593-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis and biological evaluation of N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid as a potential inhibitor of GAR Tfase and the de novo purine biosynthetic pathway.
  • [MeSH-minor] Humans. Molecular Structure. Phosphoribosylaminoimidazolecarboxamide Formyltransferase. Phosphoribosylglycinamide Formyltransferase. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Structure-Activity Relationship. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15848772.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 63536
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / N-(4-(5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl)benzoyl)-L-glutamic acid; 0 / Purines; 0 / Pyrimidines; 3KX376GY7L / Glutamic Acid; EC 2.1.2.- / Hydroxymethyl and Formyl Transferases; EC 2.1.2.2 / Phosphoribosylglycinamide Formyltransferase; EC 2.1.2.3 / Phosphoribosylaminoimidazolecarboxamide Formyltransferase
  •  go-up   go-down


71. Bongers ME, Francken AB, Rouwé C, Kamps WA, Postma A: Reduction of adult height in childhood acute lymphoblastic leukemia survivors after prophylactic cranial irradiation. Pediatr Blood Cancer; 2005 Aug;45(2):139-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of adult height in childhood acute lymphoblastic leukemia survivors after prophylactic cranial irradiation.
  • [MeSH-major] Cranial Irradiation / adverse effects. Growth Disorders / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy


72. Sasaki E, Yatabe Y, Hashimoto M, Yamashita Y, Hasegawa Y, Kojima H, Nagasawa T, Mori N: Development-dependent expression of cyclin D3 in precursor T-cell lymphoblastic leukemia/lymphoma. Pathol Int; 2007 Feb;57(2):53-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development-dependent expression of cyclin D3 in precursor T-cell lymphoblastic leukemia/lymphoma.
  • Therefore, cyclin D3 expression was examined in 36 human precursor T-lymphoblastic leukemia/lymphomas (T-LBLL), a neoplastic counterpart of T cells at the early developmental stages of differentiation.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Cyclins / metabolism. Leukemia, Lymphoid / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17300668.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD79; 0 / CCND3 protein, human; 0 / Ccnd3 protein, mouse; 0 / Cyclin D3; 0 / Cyclins; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


73. Gotman LN, Iatsyk GA, Vorob'ev VI: [Diagnosis of cryptococcal encephalitis in a patient with mature B-cell lymphoblastic leukemia]. Ter Arkh; 2010;82(1):56-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of cryptococcal encephalitis in a patient with mature B-cell lymphoblastic leukemia].
  • [MeSH-major] Cryptococcosis / diagnosis. Encephalitis / diagnosis. Magnetic Resonance Imaging / methods. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Encephalitis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20364703.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, Fungal
  •  go-up   go-down


74. Tucci F, Aricò M: Treatment of pediatric acute lymphoblastic leukemia. Haematologica; 2008 Aug;93(8):1124-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of pediatric acute lymphoblastic leukemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Haematologica. 2008 Aug;93(8):1161-8 [18556413.001]
  • [CommentOn] Haematologica. 2008 Aug;93(8):1155-60 [18519521.001]
  • (PMID = 18669975.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


75. Hong KP, Kang SH, Lee KM, Ji GY, Yoon SS, Kim JS, Son BR, Lee DG, Lee OJ, Song HG: Characterization of a Novel Monoclonal Antibody (27H2) Recognizing Human CD34 Class III Epitope. Immune Netw; 2010 Dec;10(6):239-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Monoclonal antibodies (mAbs) recognizing Class III epitope of CD34 are essential for flow cytometric diagnosis of leukemia.
  • METHODS: 27H2 mAb was developed from a mouse alternatively immunized with human acute leukemia cell lines, KG1 and Molm-1.
  • A case of bone marrow sample of acute lymphoblastic leukemia (ALL) patient was obtained at CBNU Hospital.
  • CONCLUSION: A novel murine mAb recognizing class III epitope of human CD34 with high affinity, which is useful for flow cytometric diagnosis of leukemia, was developed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Mar 15;93(6):1858-68 [10068658.001]
  • [Cites] J Immunol Methods. 1997 May 26;204(2):175-88 [9212835.001]
  • [Cites] J Hematother. 1992 Summer;1(2):115-29 [1285404.001]
  • [Cites] Br J Haematol. 1996 Sep;94(4):597-605 [8826880.001]
  • [Cites] Hematol Cell Ther. 1998 Dec;40(6):259-68 [9924925.001]
  • [Cites] Leukemia. 1992;6 Suppl 1:31-6 [1372379.001]
  • [Cites] Blood. 1990 Jun 15;75(12):2417-26 [1693532.001]
  • [Cites] Haematologica. 1991 Jul-Aug;76(4):330-3 [1724439.001]
  • [Cites] Leukemia. 1987 May;1(5):417-26 [2444831.001]
  • [Cites] Leuk Res. 1985;9(1):1-9 [3857402.001]
  • [Cites] Leuk Res. 1985;9(2):191-8 [3857408.001]
  • [Cites] Am J Pathol. 1985 Apr;119(1):1-4 [3885751.001]
  • [Cites] J Immunol. 1984 Jul;133(1):157-65 [6586833.001]
  • [Cites] Leuk Lymphoma. 1995;18 Suppl 1:25-30 [7496351.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):28-36 [7505806.001]
  • [Cites] Bone Marrow Transplant. 1995 Oct;16(4):611-6 [8528180.001]
  • [Cites] Ann N Y Acad Sci. 1995 Dec 29;770:91-8 [8597386.001]
  • [Cites] Cytometry. 1996 Jun 15;26(2):154-60 [8817092.001]
  • [Cites] J Hematother. 1996 Jun;5(3):213-26 [8817388.001]
  • [Cites] J Hematother. 1996 Dec;5(6):599-603 [9117248.001]
  • [Cites] J Biol Regul Homeost Agents. 2001 Jan-Mar;15(1):1-13 [11388737.001]
  • (PMID = 21286385.001).
  • [ISSN] 2092-6685
  • [Journal-full-title] Immune network
  • [ISO-abbreviation] Immune Netw
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3026944
  • [Keywords] NOTNLM ; 27H2 / CD34 / Class III epitope / Diagnosis / Leukemia / Monoclonal antibody
  •  go-up   go-down


76. Ozgen IT, Dagdemir A, Elli M, Saraymen R, Pinarli FG, Fisgin T, Albayrak D, Acar S: Hair selenium status in children with leukemia and lymphoma. J Pediatr Hematol Oncol; 2007 Aug;29(8):519-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hair selenium status in children with leukemia and lymphoma.
  • Thirty patients with leukemia (n=17) and lymphoma (n=13), and 25 healthy controls were enrolled to the study.
  • Children with lymphoma had lower Se than the children with acute lymphoblastic leukemia but not statistically significant [547.03+/-283.67 ng/g vs. 758.67+/-361.05 ng/g (P>0.05)].
  • In this study, we found that hair Se levels of the children with leukemia and lymphoma, especially those of malnourished patients, were lower than those of controls.
  • [MeSH-major] Child Nutrition Disorders / complications. Hodgkin Disease / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Selenium / deficiency

  • MedlinePlus Health Information. consumer health - Child Nutrition.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762491.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] H6241UJ22B / Selenium
  •  go-up   go-down


77. Pavlů J, Marin D: Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials. Clin Lymphoma Myeloma; 2009 Dec;9(6):417-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials.
  • Imatinib is currently regarded as the best initial treatment for patients with chronic myeloid leukemia (CML).
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Thiazoles / therapeutic use
  • [MeSH-minor] Clinical Trials as Topic. Dasatinib. Female. Follow-Up Studies. Humans. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


78. Romagnani P, Lazzeri E, Mazzinghi B, Lasagni L, Guidi S, Bosi A, Cirami C, Salvadori M: Nephrotic syndrome and renal failure after allogeneic stem cell transplantation: novel molecular diagnostic tools for a challenging differential diagnosis. Am J Kidney Dis; 2005 Sep;46(3):550-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Infiltrating mononuclear cells in renal tissue consisted of T cells expressing DNA levels of a Y chromosome-specific gene quantitatively similar to those observed in a male subject, showing that these cells derived from the transplant donor and definitely excluding leukemia relapse.
  • [MeSH-minor] Adult. Chromosomes, Human, Y / genetics. DNA / analysis. Diagnosis, Differential. Disease Progression. Female. Genetic Markers. Humans. Leukemic Infiltration / diagnosis. Living Donors. Male. Polymerase Chain Reaction. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129218.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 9007-49-2 / DNA
  •  go-up   go-down


79. El-Sissy A, El-Mashari M, Bassuni W, El-Swaayed A: Molecular detection of BCR/ABL fusion gene in Saudi acute lymphoblastic leukemia patients. J Egypt Natl Canc Inst; 2006 Jun;18(2):109-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular detection of BCR/ABL fusion gene in Saudi acute lymphoblastic leukemia patients.
  • A fraction of acute lymphoblastic leukemia (ALL) cases carry the translocation t(9;22) (q34;q11.2) which juxtaposes the ABL proto-oncogene to the BCR gene generating a chimeric gene, BCR/ABL.
  • PATIENTS AND METHODS: Twenty newly diagnosed ALL patients, 16 adult and 4 paediatric cases, were included in the study, 11 cases (55%) were of precursor B phenotype, 8 cases (40%) belonged to T lineage, while one case was biphenotypic expressing mainly precursor B cell markers tether with CD13, CD33, CD117, Detection of BCR/ABL fusion gene was done using interphase FISH technique and was confirmed molecularly using the RT-PCR technique.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496935.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, Differentiation, B-Lymphocyte; 0 / RNA, Messenger; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


80. Hoelzer D, Gökbuget N: T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Clin Lymphoma Myeloma; 2009;9 Suppl 3:S214-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?
  • T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are considered the same disease, differing by the extent of bone marrow infiltration.
  • Treatment approaches in T-LBL changed from conventional non-Hodgkin lymphoma (NHL) protocols to intensive NHL protocols but recently to ALL-designed protocols.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778844.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


81. Ma XL, Wang B, Guo HY, Zhang YH, Zhu GH, Duan YL, Yang J, Zhang DW, Jin L, Zhang R, Zhang L, Xie J, Wu MY: [Tolerability of 6-mercaptopurine in children with acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2010 Apr;48(4):289-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tolerability of 6-mercaptopurine in children with acute lymphoblastic leukemia].
  • OBJECTIVE: 6-Mercaptopurine (6-MP) has been the backbone of maintenance chemotherapy for acute lymphoblastic leukemia (ALL), the response to 6-MP is highly variable, adverse events leading to discontinuation or dose-reduction (children intolerant) of 6-MP occur in many children with ALL.
  • [MeSH-major] 6-Mercaptopurine / pharmacology. Antimetabolites, Antineoplastic / pharmacology. Drug Resistance, Neoplasm. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654019.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine
  •  go-up   go-down


82. Baldus CD, Thibaut J, Goekbuget N, Stroux A, Schlee C, Mossner M, Burmeister T, Schwartz S, Bloomfield CD, Hoelzer D, Thiel E, Hofmann WK: Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica; 2009 Oct;94(10):1383-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia.
  • BACKGROUND: NOTCH1 mutations have been associated with a favorable outcome in pediatric acute T-lymphoblastic leukemia.
  • However, the results of studies on the prognostic significance of NOTCH1 mutations in adult T-lymphoblastic leukemia remain controversial.
  • DESIGN AND METHODS: Here we have investigated the prognostic impact of mutations in the NOTCH1 pathway, in particular, the NOTCH1 and FBXW7 genes, in a large cohort of adult patients with T-lymphoblastic leukemia (n=126).
  • CONCLUSIONS: NOTCH1 and FBXW7 mutations were not predictive of outcome in the overall cohort of adult patients with T-lymphoblastic leukemia, but there was a trend towards a favorable prognostic impact of NOTCH1-FBXW7 mutations in the small subgroup of patients with low-risk ERG/BAALC expression status.
  • Our findings further confirm the high frequency of NOTCH1 mutations in adult T-lymphoblastic leukemia.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Mutation / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Sep 21;276(38):35847-53 [11461910.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:162-92 [12446423.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1589-95 [12886247.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]
  • [Cites] Semin Cell Dev Biol. 2005 Jun;16(3):323-33 [15840441.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1841-3 [16079893.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Leukemia. 2006 Mar;20(3):537-9 [16424867.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3043-9 [16707600.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4714-20 [16954520.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:169-77 [17124057.001]
  • [Cites] Lancet. 2006 Nov 25;368(9550):1894-907 [17126723.001]
  • [Cites] Nat Rev Drug Discov. 2007 Feb;6(2):149-65 [17268486.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1879-82 [17332312.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5611-6 [17575125.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] J Exp Med. 2007 Nov 26;204(12):2875-88 [17984302.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6964-9 [18056171.001]
  • [Cites] Leukemia. 2008 Jan;22(1):124-31 [17928886.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1154-60 [18368072.001]
  • [Cites] Blood. 2008 Aug 1;112(3):733-40 [18411416.001]
  • [Cites] Nat Med. 2009 Jan;15(1):50-8 [19098907.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [CommentIn] Haematologica. 2009 Oct;94(10):1338-40 [19794079.001]
  • (PMID = 19794083.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / Receptor, Notch1; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ PMC2754954
  •  go-up   go-down


83. Thornley I, Eapen M, Sung L, Lee SJ, Davies SM, Joffe S: Private cord blood banking: experiences and views of pediatric hematopoietic cell transplantation physicians. Pediatrics; 2009 Mar;123(3):1011-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Few respondents would choose autologous cord blood over alternative stem cell sources for treatment of acute lymphoblastic leukemia in second remission.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Children's Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Perinat Med. 2004;32(5):430-3 [15493721.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Mar;14(3):356-63 [18275904.001]
  • [Cites] Blood. 1985 Jul;66(1):115-9 [4005425.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1166-72 [1878583.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):323-9 [1732433.001]
  • [Cites] Blood. 1994 Jul 15;84(2):380-3 [8025266.001]
  • [Cites] Acta Haematol. 1996;95(3-4):157-63 [8677736.001]
  • [Cites] Br J Haematol. 1996 Jul;94(1):65-72 [8757510.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 May-Jun;19(3):183-6 [9201137.001]
  • [Cites] Int J Gynaecol Obstet. 1997 Aug;58(2):257-9 [9252269.001]
  • [Cites] JAMA. 1997 Sep 17;278(11):938-43 [9302248.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Eur J Cancer. 1997 Oct;33(12):2024-30 [9516847.001]
  • [Cites] N Engl J Med. 1999 May 13;340(19):1521-4 [10320393.001]
  • [Cites] Pediatrics. 1999 Jul;104(1 Pt 1):116-8 [10390273.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2255-7 [15564539.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2265-75 [15564543.001]
  • [Cites] Bone Marrow Transplant. 1999 Nov;24(9):1041 [10556967.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):321-8 [11091219.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2247-56 [11187916.001]
  • [Cites] Br J Haematol. 2001 Sep;114(3):706-11 [11553002.001]
  • [Cites] Blood. 2002 May 15;99(10):3801-5 [11986239.001]
  • [Cites] Am J Obstet Gynecol. 2002 Dec;187(6):1642-6 [12501077.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Jan;25(1):8-13 [12544767.001]
  • [Cites] Lancet. 2003 Jan 18;361(9353):250-2 [12547553.001]
  • [Cites] Transfusion. 2004 Apr;44(4):518-25 [15043567.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2276-85 [15564544.001]
  • [Cites] PLoS Med. 2005 Feb;2(2):e44 [15737000.001]
  • [Cites] BMJ. 2006 Oct 14;333(7572):801-4 [17038739.001]
  • [Cites] Pediatrics. 2007 Jan;119(1):e296-300 [17200253.001]
  • [Cites] Pediatrics. 2007 Jan;119(1):165-70 [17200285.001]
  • [Cites] Lancet. 2007 Jun 9;369(9577):1947-54 [17560447.001]
  • [Cites] J Perinat Med. 2007;35(4):314-21 [17511596.001]
  • [Cites] Obstet Gynecol. 2008 Jan;111(1):178-82 [18165407.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Nov;10(11):741-2 [15505604.001]
  • (PMID = 19255033.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA076518-14; United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-14
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS297589; NLM/ PMC3120215
  •  go-up   go-down


84. Moon H, Cho J, Hur M, Yun YM, Han SH, Lee MH: Multiple unrelated chromosomal abnormalities in host cells after cord blood transplantation. J Pediatr Hematol Oncol; 2010 May;32(4):332-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY: We experienced a 16-year-old patient with T-cell acute lymphoblastic leukemia, who had multiple unrelated chromosomal abnormalities in host cells after chemotherapy and cord blood transplantation (CBT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Aberrations. Cord Blood Stem Cell Transplantation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20418786.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Li G, Hundemer M, Wolfrum S, Ho AD, Goldschmidt H, Witzens-Harig M: Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A). Ann Hematol; 2006 Sep;85(9):583-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PBK/TOPK is overexpressed in Burkitt lymphoma, acute lymphoblastic leukemia, and MM; PAK2 is expressed in malignant lymphatic cells.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16718496.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Epitopes, T-Lymphocyte; 0 / HLA-A2 Antigen; EC 2.7.11.1 / PAK2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / p21-Activated Kinases
  •  go-up   go-down


86. Offidani M, Corvatta L, Malerba L, Marconi M, Catarini M, Centurioni R, Leoni F, Scortechini AR, Masia MC, Leoni P: Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL). Leuk Lymphoma; 2005 Feb;46(2):233-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL).
  • Acute lymphoblastic leukemia (ALL) represents a rare malignancy in the elderly and few authors have specifically focused on the treatment of ALL in this setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621806.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Liposomes; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


87. Bassal M, La MK, Whitlock JA, Sather HN, Heerema NA, Gaynon PS, Stork LC: Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer; 2005 Jan;44(1):21-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients with Down syndrome (DS) and standard risk (SR) acute lymphoblastic leukemia (ALL-DS) are reported to have inferior event free (EFS) and overall survival (OS) compared to patients without DS (ALL-NDS).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Down Syndrome / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology


88. Fazlina N, Maha A, Zarina AL, Hamidah A, Zulkifli SZ, Cheong SK, Ainoon O, Jamal R, Hamidah NH: Assessment of P-gp and MRP1 activities using MultiDrugQuant Assay Kit: a preliminary study of correlation between protein expressions and its functional activities in newly diagnosed acute leukaemia patients. Malays J Pathol; 2008 Dec;30(2):87-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of P-gp and MRP1 activities using MultiDrugQuant Assay Kit: a preliminary study of correlation between protein expressions and its functional activities in newly diagnosed acute leukaemia patients.
  • Multidrug resistance (MDR) is believed to be responsible for poor response of patients towards chemotherapy particularly patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
  • We studied P-gp and multidrug resistance-associated protein 1 (MRP1) expression and functional activities in 43 newly diagnosed acute leukemia cases (19 paediatric ALL cases and 24 adult AML cases).
  • [MeSH-major] Leukemia, Myeloid, Acute / metabolism. Multidrug Resistance-Associated Proteins / biosynthesis. P-Glycoprotein / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Reagent Kits, Diagnostic

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19291917.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / Reagent Kits, Diagnostic; 0 / multidrug resistance-associated protein 1
  •  go-up   go-down


89. Scupoli MT, Donadelli M, Cioffi F, Rossi M, Perbellini O, Malpeli G, Corbioli S, Vinante F, Krampera M, Palmieri M, Scarpa A, Ariola C, Foà R, Pizzolo G: Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways. Haematologica; 2008 Apr;93(4):524-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways.
  • BACKGROUND: Cytokines released in the bone marrow and thymic microenvironments play a key role in the growth of T-cell acute lymphoblastic leukemia.
  • Among such cytokines, interleukin-8 is highly expressed in T-cell acute lymphoblastic leukemia cells refractory to chemotherapy.
  • In this study we explored whether bone marrow stromal cells can regulate IL-8 expression in T-cell acute lymphoblastic leukemia and investigated the role of the stromal CXCL12 chemokine in this event.
  • DESIGN AND METHODS: We analyzed the expression of interleukin-8 in primary cells from ten adult patients with T-cell acute lymphoblastic leukemia when these cells were cultured with bone marrow stromal cells or stimulated with exogenous CXCL12.
  • RESULTS: Bone marrow stromal cells upregulated interleukin-8 mRNA in T-cell acute lymphoblastic leukemia cells through the activity of CXCR4, the CXCL12 receptor, as assessed by the use of neutralizing antibodies.
  • Exogenous CXCL12 induced a significant increase in the production of IL-8 mRNA and protein in all T-cell acute lymphoblastic leukemia cases.
  • CONCLUSIONS: Interleukin-8 is physiologically regulated by the CXCL12/CXCR4 axis and the nuclear factor-kappaB and JNK/AP-1 pathways are required for interleukin-8 expression in T-cell acute lymphoblastic leukemia.
  • We propose that, by upregulating interleukin-8, the bone marrow microenvironment and the CXCL12/CXCR4 axis may play a role in the pathogenesis of T-cell acute lymphoblastic leukemia.
  • [MeSH-major] Bone Marrow Cells / metabolism. Chemokine CXCL12 / physiology. Gene Expression Regulation, Leukemic / physiology. Interleukin-8 / biosynthesis. JNK Mitogen-Activated Protein Kinases / physiology. Leukemia-Lymphoma, Adult T-Cell / metabolism. NF-kappa B / physiology. Neoplasm Proteins / physiology. Receptors, CXCR4 / physiology. Stromal Cells / metabolism. Transcription Factor AP-1 / physiology. Up-Regulation / physiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Apr;93(4):493-7 [18379008.001]
  • (PMID = 18322253.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / CXCR4 protein, human; 0 / Chemokine CXCL12; 0 / Interleukin-8; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, CXCR4; 0 / Recombinant Fusion Proteins; 0 / Transcription Factor AP-1; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  •  go-up   go-down


90. Desandes E, Lacour B, Belot A, White-Koning M, Velten M, Tretarre B, Sauleau EA, Maarouf N, Guizard AV, Delafosse P, Danzon A, Cotte C, Boutreux S, Brugières L: [Cancer incidence and survival among adolescents and young adults in France (1978-1997)]. Bull Cancer; 2007 Apr;94(4):331-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Incidence et survie des cancers de l'adolescent et de l'adulte jeune en France (1978-1997).
  • Noteworthy, results in adolescents and young adults are poor compared to the ones from their younger counterparts, especially in patients with acute lymphoblastic leukemia, non-Hodgkin lymphoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, and astrocytoma.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449435.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


91. Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, Koo K, Allen CG, Gale RE, Buck G, Richards S, Paietta E, Rowe JM, Tallman MS, Goldstone AH, Ferrando AA, Linch DC: Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol; 2009 Sep 10;27(26):4352-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
  • PURPOSE: Notch pathway activation by mutations in either NOTCH1 and/or FBXW7 is one of the most common molecular events in T-cell acute lymphoblastic leukemia (T-ALL) and, in pediatric disease, predicts for favorable outcome.
  • We sought to evaluate the outcome according to mutation status of patients with adult T-ALL treated on the United Kingdom Acute Lymphoblastic Leukaemia XII (UKALLXII)/Eastern Cooperative Oncology Group (ECOG) E2993 protocol.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3043-9 [16707600.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Nat Med. 2007 Jan;13(1):70-7 [17173050.001]
  • [Cites] Blood. 2007 Feb 1;109(3):910-5 [17023577.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5611-6 [17575125.001]
  • [Cites] Blood. 2007 Jul 1;110(1):278-86 [17363738.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1262-70 [17456725.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6964-9 [18056171.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Leuk Res. 2008 Nov;32(11):1751-5 [18485478.001]
  • [Cites] Blood. 2008 Aug 1;112(3):733-40 [18411416.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4386-93 [12036866.001]
  • [Cites] Haematologica. 2002 Nov;87(11):1126-34 [12414341.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2149-56 [14576730.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] Leukemia. 1998 Apr;12(4):463-73 [9557602.001]
  • [Cites] Leukemia. 2006 Mar;20(3):537-9 [16424867.001]
  • (PMID = 19635999.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00002514
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856; United States / NCI NIH HHS / CA / R01 CA129382; United Kingdom / Medical Research Council / / ; United Kingdom / Medical Research Council / / G0500389; United States / NCI NIH HHS / CA / R01CA120196; United States / NCI NIH HHS / CA / R01CA129382; United States / NCI NIH HHS / CA / R01 CA120196; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / R01 CA120196-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; EC 2.3.2.27 / Ubiquitin-Protein Ligases; EC 6.3.2.19 / FBXW7 protein, human
  • [Other-IDs] NLM/ PMC2744275
  •  go-up   go-down


92. Rojas-Morales T, Lugo Z, Santana Y, Navas R, Zambrano O, Viera N, García I: Capacity buffer of the saliva in children and adolescents with cancer: Variations induced by the administration of metotrexate or cyclophosphamide. Med Oral Patol Oral Cir Bucal; 2005;10 Suppl 2:E103-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sample was composed by 24 children, ages between 2 and 16 years, with diagnostic of Leukemia and Lymphomas attending to The Autonomous Service of University Hospital of Maracaibo and Hospital of Pediatric Specialties.
  • [MeSH-major] Acid-Base Equilibrium / drug effects. Antineoplastic Agents, Alkylating / pharmacology. Cyclophosphamide / pharmacology. Lymphoma, Non-Hodgkin / drug therapy. Methotrexate / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Saliva / chemistry. Saliva / drug effects

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15995568.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Buffers; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


93. Mehta PA, Davies SM, Kumar A, Devidas M, Lee S, Zamzow T, Elliott J, Villanueva J, Pullen J, Zewge Y, Filipovich A, Children's Oncology Group: Perforin polymorphism A91V and susceptibility to B-precursor childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia; 2006 Sep;20(9):1539-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perforin polymorphism A91V and susceptibility to B-precursor childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.
  • A frequent polymorphism, A91V (C to T transition at position 272), may impair processing of perforin protein to the active form, and has been suggested to increase susceptibility to childhood acute lymphoblastic leukemia (ALL).
  • To investigate the role of A91V in ALL, we genotyped 2272 children with de novo ALL registered on the Pediatric Oncology Group ALL Classification study P9900 and 655 normal controls.


94. Hawwa AF, Collier PS, Millership JS, McCarthy A, Dempsey S, Cairns C, McElnay JC: Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Br J Clin Pharmacol; 2008 Dec;66(6):826-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.
  • AIMS: To investigate the population pharmacokinetics of 6-mercaptopurine (6-MP) active metabolites in paediatric patients with acute lymphoblastic leukaemia (ALL) and examine the effects of various genetic polymorphisms on the disposition of these metabolites.
  • [MeSH-major] 6-Mercaptopurine / analogs & derivatives. Antimetabolites, Antineoplastic / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Methyltransferases / pharmacokinetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):1983-5 [10580012.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Feb;19(1):23-37 [17305252.001]
  • [Cites] J Pharmacokinet Biopharm. 1981 Aug;9(4):503-12 [7310648.001]
  • [Cites] N Engl J Med. 1983 Apr 28;308(17):1005-9 [6572786.001]
  • [Cites] Clin Pharmacol Ther. 1986 Sep;40(3):287-92 [3461899.001]
  • [Cites] Biochem Pharmacol. 1986 Oct 15;35(20):3533-41 [3533081.001]
  • [Cites] Science. 1989 Apr 7;244(4900):41-7 [2649979.001]
  • [Cites] Clin Pharmacokinet. 1989 Jun;16(6):327-36 [2661101.001]
  • [Cites] J Clin Oncol. 1989 Dec;7(12):1816-23 [2585022.001]
  • [Cites] J Pediatr. 1991 Dec;119(6):985-9 [1960624.001]
  • [Cites] Nutrition. 1989 Sep-Oct;5(5):303-11; discussion 312-3 [2520314.001]
  • [Cites] Br J Cancer Suppl. 1992 Aug;18:S23-9 [1503923.001]
  • [Cites] Eur J Clin Pharmacol. 1992;43(4):329-39 [1451710.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(6):411-8 [8258188.001]
  • [Cites] Clin Pharmacokinet. 1996 May;30(5):329-32 [8743333.001]
  • [Cites] Eur J Pharm Sci. 1999 Aug;8(4):329-34 [10425383.001]
  • [Cites] Cancer Res. 1958 Aug;18(7):853-6 [13573353.001]
  • [Cites] Med Sci Monit. 2004 Nov;10(11):RA247-54 [15507865.001]
  • [Cites] Oncogene. 2006 Mar 13;25(11):1629-38 [16550163.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Sep 1;24(5):715-29 [16918876.001]
  • [Cites] Pediatr Int. 2001 Dec;43(6):673-7 [11737747.001]
  • (PMID = 18823306.001).
  • [ISSN] 1365-2125
  • [Journal-full-title] British journal of clinical pharmacology
  • [ISO-abbreviation] Br J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 6V404DV25O / 6-methylthiopurine; E7WED276I5 / 6-Mercaptopurine; EC 2.1.1.- / Methyltransferases; EC 2.1.1.67 / thiopurine methyltransferase
  • [Other-IDs] NLM/ PMC2675766
  •  go-up   go-down


95. Nahi H, Hägglund H, Ahlgren T, Bernell P, Hardling M, Karlsson K, Lazarevic VLj, Linderholm M, Smedmyr B, Aström M, Hallböök H: An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients. Haematologica; 2008 Nov;93(11):1734-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients.
  • In acute lymphoblastic leukemia, besides age and white cell count at diagnosis, the cytogenetic abnormalities t(9;22)/BCR-ABL and t(4;11)/MLL-AF4 are important prognostic markers and are often included in the treatment stratification of patients with adult acute lymphoblastic leukemia.
  • Deletions in 9p are seen in about 9% of cases of adult acute lymphoblastic leukemia, but their prognostic impact has been controversial.
  • Cytogenetic data from 381 patients diagnosed with B-precursor acute lymphoblastic leukemia were reviewed.
  • Our data suggest that chromosomal abnormalities involving 9p may have a significant negative impact on survival in adult B-precursor acute lymphoblastic leukemia.
  • [MeSH-major] Burkitt Lymphoma / genetics. Burkitt Lymphoma / mortality. Chromosomes, Human, Pair 9. Sequence Deletion

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728022.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


96. Cartwright MS, Jeffery DR, Lewis ZT, Koty PP, Stewart WT, Molnár I: Mitoxantrone for multiple sclerosis causing acute lymphoblastic leukemia. Neurology; 2007 May 8;68(19):1630-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitoxantrone for multiple sclerosis causing acute lymphoblastic leukemia.
  • [MeSH-major] Mitoxantrone / adverse effects. Multiple Sclerosis / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology


97. Heerema NA, Bernheim A, Lim MS, Look AT, Pasqualucci L, Raetz E, Sanger WG, Cairo MS: State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays in childhood lymphoma: summary report of workshop at the First International Symposium on childhood and adolescent non-Hodgkin lymphoma, April 9, 2003, New York City, NY. Pediatr Blood Cancer; 2005 Oct 15;45(5):616-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays in childhood lymphoma: summary report of workshop at the First International Symposium on childhood and adolescent non-Hodgkin lymphoma, April 9, 2003, New York City, NY.
  • BACKGROUND: A significant number of studies describe the cytogenetics and molecular genetics of adult non-Hodgkin lymphoma (NHL); however, similar knowledge is lacking regarding pediatric NHL.
  • METHODS: A workshop to discuss the "State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays" in pediatric NHL was held in conjunction with the First International Symposium on Childhood and Adolescent Non-Hodgkin Lymphoma on April 9, 2003 in New York City.
  • RESULTS: Cytogenetic characteristics of pediatric NHL include 14q11.2 rearrangements in T-cell lymphoblastic leukemia/lymphomas (LBL), ALK rearrangements in anaplastic large cell lymphomas (ALCL), and CMYC translocations in both Burkitt and Burkitt-like lymphomas (BL/BLL).
  • Pediatric diffuse large B-cell lymphoma (DLBCL) is cytogenetically different from DLBCL in adults, suggesting a different disease in children.
  • Microarray studies demonstrate three types of T-cell leukemia, the leukemic counterpart of LBL, that block T-cell differentiation at different stages of T-cell development, corresponding to LYL, TAL1, and HOX-expressing leukemias.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adolescent. Basic Helix-Loop-Helix Transcription Factors. Burkitt Lymphoma / genetics. Child. Cytogenetic Analysis. DNA-Binding Proteins / genetics. Gene Rearrangement. Homeodomain Proteins / genetics. Humans. Intracellular Signaling Peptides and Proteins. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Microarray Analysis. Molecular Biology. Neoplasm Proteins / genetics. Oncogene Proteins / genetics. Oncogene Proteins, Fusion / genetics

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Hodgkin lymphoma, childhood.
  • Genetic Alliance. consumer health - Non-Hodgkin lymphoma, childhood.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127683.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R13-CA10195-01
  • [Publication-type] Congresses; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / LYL1 protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins; 0 / Oncogene Proteins, Fusion; 0 / STIL protein, human; 0 / TLX3 protein, human
  •  go-up   go-down


98. Cullion K, Draheim KM, Hermance N, Tammam J, Sharma VM, Ware C, Nikov G, Krishnamoorthy V, Majumder PK, Kelliher MA: Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood; 2009 Jun 11;113(24):6172-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations in NOTCH1 are frequently detected in patients with T-cell acute lymphoblastic leukemia (T-ALL) and in mouse T-ALL models.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] Blood. 2007 Jul 1;110(1):278-86 [17363738.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] Blood. 2008 Aug 1;112(3):733-40 [18411416.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1906-13 [10961893.001]
  • [Cites] Nat Immunol. 2000 Aug;1(2):138-44 [11248806.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):655-64 [12509463.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1909-11 [14604958.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12876-82 [14709552.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):587-96 [15193261.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9265-73 [15485896.001]
  • [Cites] Toxicol Sci. 2004 Nov;82(1):341-58 [15319485.001]
  • [Cites] Mol Cell Biol. 1989 May;9(5):2124-32 [2501659.001]
  • [Cites] EMBO J. 1990 Oct;9(10):3343-51 [2209547.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 15;88(10):4367-71 [2034676.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1477-88 [1886719.001]
  • [Cites] Mol Cell Biol. 1991 Nov;11(11):5462-9 [1922059.001]
  • [Cites] Oncogene. 1991 Oct;6(10):1887-93 [1923511.001]
  • [Cites] Blood. 1992 Mar 1;79(5):1327-33 [1311214.001]
  • [Cites] Blood. 1995 Jul 15;86(2):666-76 [7605997.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2283-91 [8642337.001]
  • [Cites] EMBO J. 1996 Oct 1;15(19):5160-6 [8895560.001]
  • [Cites] Cell. 1996 Nov 1;87(3):483-92 [8898201.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5113-9 [8912842.001]
  • [Cites] EMBO J. 1997 May 1;16(9):2408-19 [9171354.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):964-8 [15959516.001]
  • [Cites] Nat Immunol. 2005 Sep;6(9):881-8 [16056227.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):209-20 [16354692.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6688-93 [16618932.001]
  • [Cites] Blood. 2006 May 15;107(10):4115-21 [16449526.001]
  • [Cites] Oncogene. 2006 May 18;25(21):3023-31 [16407836.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4642-51 [16738328.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9262-7 [16751266.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8022-31 [16954387.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1032-7 [17183313.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1083-7 [17183323.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):52-9 [17178457.001]
  • [Cites] Nature. 2007 Feb 15;445(7129):781-4 [17259972.001]
  • [Cites] Chem Biol. 2007 Feb;14(2):209-19 [17317574.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4753-60 [17311993.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5611-6 [17575125.001]
  • [CommentIn] Blood. 2009 Jun 11;113(24):6044-5 [19520812.001]
  • (PMID = 19246562.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096899; United States / NCI NIH HHS / CA / CA096899; United States / NIDDK NIH HHS / DK / P30DK32529
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Carrier Proteins; 0 / Cyclic S-Oxides; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / MRK 003; 0 / Proto-Oncogene Proteins; 0 / Receptor, Notch1; 0 / Tal1 protein, mouse; 0 / Thiadiazoles; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 3.4.- / Amyloid Precursor Protein Secretases
  • [Other-IDs] NLM/ PMC2699237
  •  go-up   go-down


99. Kurekci AE, Atay AA, Demirkaya E, Sarici SU, Ozcan O: Immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia and mumps. J Pediatr Hematol Oncol; 2006 Mar;28(3):170-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia and mumps.
  • We report for the first time a child with acute lymphoblastic leukemia who developed immune thrombocytopenic purpura due to mumps during the maintenance phase of acute lymphoblastic leukemia treatment.
  • [MeSH-major] Mumps / complications. Neoplasm Recurrence, Local / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Purpura, Thrombocytopenic, Idiopathic / etiology


100. Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Mano H, Furukawa Y: Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Invest New Drugs; 2007 Feb;25(1):31-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
  • We studied the cytotoxic interaction of FK228 in combination with conventional antileukemic agents using human promyelocytic leukemia HL60, Philadelphia chromosome-positive (Ph(+)) chronic myelogenous leukemia KU-812, T-cell lymphoblastic leukemia MOLT3 and Burkitt's lymphoma Raji cell lines.
  • For the combination of FK228 and imatinib, Ph(+) leukemia KU812, K562 and TCC-S cell lines were used.
  • FK228 was additive with imatinib in all three Ph(+) leukemia cells.
  • [MeSH-minor] 6-Mercaptopurine / pharmacology. Apoptosis / drug effects. Benzamides. Camptothecin / analogs & derivatives. Camptothecin / pharmacology. Carboplatin / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Cyclophosphamide / analogs & derivatives. Cyclophosphamide / pharmacology. Cytarabine / pharmacology. Dose-Response Relationship, Drug. Doxorubicin / pharmacology. Drug Synergism. Etoposide / pharmacology. HL-60 Cells. Humans. Imatinib Mesylate. K562 Cells. Leukemia / pathology. Lymphoma / pathology. Piperazines / pharmacology. Pyrimidines / pharmacology. Time Factors

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Aug 15;94(4):1401-8 [10438728.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Jan;5(1):85-91 [422420.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2865-8 [11675364.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2118-26 [12727828.001]
  • [Cites] Science. 1996 Apr 19;272(5260):371-2 [8602525.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):718-28 [11895901.001]
  • [Cites] Exp Cell Res. 1998 May 25;241(1):126-33 [9633520.001]
  • [Cites] Biochem Pharmacol. 2002 Oct 1;64(7):1079-90 [12234611.001]
  • [Cites] Curr Opin Genet Dev. 1999 Feb;9(1):40-8 [10072350.001]
  • [Cites] Trends Endocrinol Metab. 2001 Sep;12(7):294-300 [11504668.001]
  • [Cites] J Antibiot (Tokyo). 1994 Mar;47(3):301-10 [7513682.001]
  • [Cites] Oncogene. 2003 Jun 26;22(26):4074-82 [12821941.001]
  • [Cites] Jpn J Cancer Res. 2000 Nov;91(11):1154-60 [11092981.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):504-13 [11929951.001]
  • [Cites] Blood. 2005 Feb 1;105(3):959-67 [15466934.001]
  • [Cites] Int J Cancer. 2003 Mar 20;104(2):238-42 [12569581.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):351-6 [3422052.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):2705-12 [15517875.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):817-25 [10952788.001]
  • [Cites] J Antibiot (Tokyo). 1994 Mar;47(3):315-23 [8175484.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 3;300(1):241-6 [12480550.001]
  • [Cites] Pharmacol Rev. 1989 Jun;41(2):93-141 [2692037.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6264-77 [12214267.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):512-24 [16186804.001]
  • [Cites] Blood. 2001 Apr 1;97(7):1999-2007 [11264164.001]
  • [Cites] Blood. 2003 Jul 15;102(2):652-8 [12649137.001]
  • [Cites] J Cell Physiol. 2005 May;203(2):387-97 [15515013.001]
  • [Cites] Cancer Biol Ther. 2002 Nov-Dec;1(6):665-8 [12642691.001]
  • [Cites] Leuk Res. 1991;15(11):1059-66 [1961009.001]
  • [Cites] Int J Cancer. 2002 Jan 20;97(3):290-6 [11774279.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7994-8004 [15585635.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1210-6 [10922406.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):91-8 [9654107.001]
  • [Cites] Acta Haematol. 2006;115(1-2):78-90 [16424655.001]
  • (PMID = 16865529.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Depsipeptides; 0 / Histone Deacetylase Inhibitors; 0 / Piperazines; 0 / Pyrimidines; 04079A1RDZ / Cytarabine; 0H43101T0J / irinotecan; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8A1O1M485B / Imatinib Mesylate; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; CX3T89XQBK / romidepsin; E7WED276I5 / 6-Mercaptopurine; U880A4FUDA / perfosfamide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down






Advertisement